1
|
Díaz-Torrealba R, Marcobal JR, Gallego J. Modelling Asphalt Overlay As-Built Roughness Based on Profile Transformation-Case for Paver Using Automatic Levelling System. Sensors (Basel) 2024; 24:2131. [PMID: 38610345 PMCID: PMC11014191 DOI: 10.3390/s24072131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/30/2024] [Revised: 03/08/2024] [Accepted: 03/20/2024] [Indexed: 04/14/2024]
Abstract
The as-built roughness, or smoothness obtained during pavement construction, plays an important role in road engineering since it serves as an indicator for both the level of service provided to users and the overall standard of construction quality. Being able to predict as-built roughness is therefore important for supporting pavement design and management decision making. An as-built IRI prediction model for asphalt overlays based on profile transformation was proposed in a previous study. The model, used as basis for this work, was developed for the case of wheeled pavers without automatic screed levelling. This study presents further development of the base prediction model, including the use of an automatic screed control system through a long-distance averaging mobile reference. Formulation of linear systems that constitute the model are presented for the case of a wheeled paver using contactless acoustic sensors set-up over a floating levelling beam attached to the paver. To calibrate the model, longitudinal profile data from the Long-Term Pavement Performance SPS-5 experiment was used, obtaining a mean error of 0.17 m/km for the predicted IRI. The results obtained demonstrate the potential of the proposed approach as a modelling alternative.
Collapse
Affiliation(s)
- Rodrigo Díaz-Torrealba
- Departamento de Ingeniería del Transporte, Territorio y Urbanismo, Universidad Politécnica de Madrid, 28040 Madrid, Spain
| | | | | |
Collapse
|
2
|
Gulisano F, Jimenez-Bermejo D, Castano-Solís S, Sánchez Diez LA, Gallego J. Development of Self-Sensing Asphalt Pavements: Review and Perspectives. Sensors (Basel) 2024; 24:792. [PMID: 38339511 PMCID: PMC10856935 DOI: 10.3390/s24030792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/24/2023] [Revised: 01/19/2024] [Accepted: 01/24/2024] [Indexed: 02/12/2024]
Abstract
The digitalization of the road transport sector necessitates the exploration of new sensing technologies that are cost-effective, high-performing, and durable. Traditional sensing systems suffer from limitations, including incompatibility with asphalt mixtures and low durability. To address these challenges, the development of self-sensing asphalt pavements has emerged as a promising solution. These pavements are composed of stimuli-responsive materials capable of exhibiting changes in their electrical properties in response to external stimuli such as strain, damage, temperature, and humidity. Self-sensing asphalt pavements have numerous applications, including in relation to structural health monitoring (SHM), traffic monitoring, Digital Twins (DT), and Vehicle-to-Infrastructure Communication (V2I) tools. This paper serves as a foundation for the advancement of self-sensing asphalt pavements by providing a comprehensive review of the underlying principles, the composition of asphalt-based self-sensing materials, laboratory assessment techniques, and the full-scale implementation of this innovative technology.
Collapse
Affiliation(s)
- Federico Gulisano
- Departamento de Ingeniería del Transporte, Territorio y Urbanismo, Universidad Politécnica de Madrid, C/Profesor Aranguren 3, 28040 Madrid, Spain;
| | - David Jimenez-Bermejo
- Information Processing and Telecommunication Center (IPTC-GATV), Universidad Politécnica de Madrid, 28040 Madrid, Spain;
| | - Sandra Castano-Solís
- Escuela Técnica Superior de Ingeniería y Diseño Industrial (ETSIDI), Universidad Politécnica de Madrid, Ronda de Valencia 3, 28012 Madrid, Spain;
| | - Luis Alberto Sánchez Diez
- Departamento de Ingeniería Civil, Hidráulica, Energía y Medio Ambiente, Universidad Politécnica de Madrid, C/Profesor Aranguren 3, 28040 Madrid, Spain;
| | - Juan Gallego
- Departamento de Ingeniería del Transporte, Territorio y Urbanismo, Universidad Politécnica de Madrid, C/Profesor Aranguren 3, 28040 Madrid, Spain;
| |
Collapse
|
3
|
Rubio JM, Lencz T, Cao H, Kraguljac N, Dhamala E, Homan P, Horga G, Sarpal DK, Argyelan M, Gallego J, Cholewa J, Barber A, Kane JM, Malhotra AK. Replication of a neuroimaging biomarker for striatal dysfunction in psychosis. Mol Psychiatry 2024:10.1038/s41380-023-02381-9. [PMID: 38177349 DOI: 10.1038/s41380-023-02381-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/19/2023] [Revised: 12/06/2023] [Accepted: 12/13/2023] [Indexed: 01/06/2024]
Abstract
To bring biomarkers closer to clinical application, they should be generalizable, reliable, and maintain performance within the constraints of routine clinical conditions. The functional striatal abnormalities (FSA), is among the most advanced neuroimaging biomarkers in schizophrenia, trained to discriminate diagnosis, with post-hoc analyses indicating prognostic properties. Here, we attempt to replicate its diagnostic capabilities measured by the area under the curve (AUC) in receiver operator characteristic curves discriminating individuals with psychosis (n = 101) from healthy controls (n = 51) in the Human Connectome Project for Early Psychosis. We also measured the test-retest (run 1 vs 2) and phase encoding direction (i.e., AP vs PA) reliability with intraclass correlation coefficients (ICC). Additionally, we measured effects of scan length on classification accuracy (i.e., AUCs) and reliability (i.e., ICCs). Finally, we tested the prognostic capability of the FSA by the correlation between baseline scores and symptom improvement over 12 weeks of antipsychotic treatment in a separate cohort (n = 97). Similar analyses were conducted for the Yeo networks intrinsic connectivity as a reference. The FSA had good/excellent diagnostic discrimination (AUC = 75.4%, 95% CI = 67.0-83.3%; in non-affective psychosis AUC = 80.5%, 95% CI = 72.1-88.0%, and in affective psychosis AUC = 58.7%, 95% CI = 44.2-72.0%). Test-retest reliability ranged between ICC = 0.48 (95% CI = 0.35-0.59) and ICC = 0.22 (95% CI = 0.06-0.36), which was comparable to that of networks intrinsic connectivity. Phase encoding direction reliability for the FSA was ICC = 0.51 (95% CI = 0.42-0.59), generally lower than for networks intrinsic connectivity. By increasing scan length from 2 to 10 min, diagnostic classification of the FSA increased from AUC = 71.7% (95% CI = 63.1-80.3%) to 75.4% (95% CI = 67.0-83.3%) and phase encoding direction reliability from ICC = 0.29 (95% CI = 0.14-0.43) to ICC = 0.51 (95% CI = 0.42-0.59). FSA scores did not correlate with symptom improvement. These results reassure that the FSA is a generalizable diagnostic - but not prognostic - biomarker. Given the replicable results of the FSA as a diagnostic biomarker trained on case-control datasets, next the development of prognostic biomarkers should be on treatment-response data.
Collapse
Affiliation(s)
- Jose M Rubio
- Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, NY, USA.
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, NY, USA.
- Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, NY, USA.
| | - Todd Lencz
- Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, NY, USA
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, NY, USA
- Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, NY, USA
| | - Hengyi Cao
- Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, NY, USA
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, NY, USA
- Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, NY, USA
| | - Nina Kraguljac
- Department of Psychiatry and Behavioral Health, The Ohio State University, Columbus, OH, USA
| | - Elvisha Dhamala
- Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, NY, USA
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, NY, USA
- Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, NY, USA
| | - Philipp Homan
- Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatric University Hospital Zurich, University of Zurich, 8032, Zurich, Switzerland
- Neuroscience Center Zurich, University of Zurich and Swiss Federal Institute of Technology Zurich, 8057, Zurich, Switzerland
| | - Guillermo Horga
- Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, NY, USA
| | - Deepak K Sarpal
- Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
| | - Miklos Argyelan
- Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, NY, USA
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, NY, USA
- Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, NY, USA
| | - Juan Gallego
- Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, NY, USA
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, NY, USA
- Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, NY, USA
| | - John Cholewa
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, NY, USA
- Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, NY, USA
| | - Anita Barber
- Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, NY, USA
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, NY, USA
- Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, NY, USA
| | - John M Kane
- Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, NY, USA
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, NY, USA
- Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, NY, USA
| | - Anil K Malhotra
- Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, NY, USA
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, NY, USA
- Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, NY, USA
| |
Collapse
|
4
|
Alfonso M, Llombart R, Gil L, Martinez I, Rodríguez C, Álvarez L, Gallego J. Tumor ablation and vertebral augmentation in the treatment of vertebral metastases: A multicenter study. Rev Esp Cir Ortop Traumatol (Engl Ed) 2023; 67:480-486. [PMID: 37084999 DOI: 10.1016/j.recot.2023.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2023] [Revised: 04/06/2023] [Accepted: 04/16/2023] [Indexed: 04/23/2023] Open
Abstract
INTRODUCTION Treatment of metastatic vertebral fractures without neural compression is performed with percutaneous cementation techniques. The increase in intratumoral pressure by these techniques can send tumor cells into the bloodstream. To prevent this dissemination and improve pain treatment, ablation techniques have been introduced that would allow the creation of a cavity in the tumor prior to cementation or directly necrosing the metastasis when its size is small. MATERIAL We present the experience with ablation of two hospitals and two different ablation techniques. The first group used radiofrequency ablation (A) in 14 patients (26 vertebrae), 4 of whom underwent vertebral arthrodesis. The second group used microwave ablation (B) in 93 patients (129 lesions) without associated vertebral instrumentation. RESULTS In group A pain improvement in VAS was 7.7-2.6 at 6 weeks. There were no complications derived from the ablation. In most cases cementation was associated. In the group B pain improvement in VAS went from 6.8-1.7 at 6 weeks. Cementation was associated in all cases. There were no complications derived from the ablation. CONCLUSION The association of ablation techniques with vertebral cementation is a safe technique that significantly improves the patient's pain and can help control the disease.
Collapse
Affiliation(s)
- M Alfonso
- Departamento de Cirugía Ortopédica y Traumatología. Clínica Universidad de Navarra, Pamplona, España.
| | - R Llombart
- Departamento de Cirugía Ortopédica y Traumatología. Clínica Universidad de Navarra, Pamplona, España
| | - L Gil
- Departamento de Cirugía Ortopédica y Traumatología. Clínica Universidad de Navarra, Pamplona, España
| | - I Martinez
- Departamento de Cirugía Ortopédica y Traumatología. Clínica Universidad de Navarra, Pamplona, España
| | - C Rodríguez
- Neurorradiologia Intervencionista. Grupo Quirón Hospitales, Madrid, España
| | - L Álvarez
- Departamento de Cirugía Ortopédica y Traumatología. Fundación Jiménez Díaz, Madrid, España
| | - J Gallego
- Departamento de Cirugía Ortopédica y Traumatología. Fundación Jiménez Díaz, Madrid, España
| |
Collapse
|
5
|
Alfonso M, Llombart R, Gil L, Martinez I, Rodríguez C, Álvarez L, Gallego J. [Translated article] Tumor ablation and vertebral augmentation in the treatment of vertebral metastases: A multicenter study. Rev Esp Cir Ortop Traumatol (Engl Ed) 2023; 67:S480-S486. [PMID: 37541348 DOI: 10.1016/j.recot.2023.08.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2023] [Accepted: 04/16/2023] [Indexed: 08/06/2023] Open
Abstract
INTRODUCTION Treatment of metastatic vertebral fractures without neural compression is performed with percutaneous cementation techniques. The increase in intratumoral pressure by these techniques can send tumor cells into the bloodstream. To prevent this dissemination and improve pain treatment, ablation techniques have been introduced that would allow the creation of a cavity in the tumor prior to cementation or directly necrosing the metastasis when its size is small. MATERIAL We present the experience with ablation of two hospitals and two different ablation techniques. The first group used radiofrequency ablation (A) in 14 patients (26 vertebrae), 4 of whom underwent vertebral arthrodesis. The second group used microwave ablation (B) in 93 patients (129 lesions) without associated vertebral instrumentation. RESULTS In group A pain improvement in VAS was 7.7-2.6 at 6 weeks. There were no complications derived from the ablation. In most cases cementation was associated. In the group B pain improvement in VAS went from 6.8 to 1.7 at 6 weeks. Cementation was associated in all cases. There were no complications derived from the ablation. CONCLUSION The association of ablation techniques with vertebral cementation is a safe technique that significantly improves the patient's pain and can help control the disease.
Collapse
Affiliation(s)
- M Alfonso
- Departamento de Cirugía Ortopédica y Traumatología, Clínica Universidad de Navarra, Pamplona, Spain.
| | - R Llombart
- Departamento de Cirugía Ortopédica y Traumatología, Clínica Universidad de Navarra, Pamplona, Spain
| | - L Gil
- Departamento de Cirugía Ortopédica y Traumatología, Clínica Universidad de Navarra, Pamplona, Spain
| | - I Martinez
- Departamento de Cirugía Ortopédica y Traumatología, Clínica Universidad de Navarra, Pamplona, Spain
| | - C Rodríguez
- Neurorradiologia Intervencionista, Grupo Quirón Hospitales, Madrid, Spain
| | - L Álvarez
- Departamento de Cirugía Ortopédica y Traumatología, Fundación Jiménez Díaz, Madrid, Spain
| | - J Gallego
- Departamento de Cirugía Ortopédica y Traumatología, Fundación Jiménez Díaz, Madrid, Spain
| |
Collapse
|
6
|
Rubio J, Lencz T, Cao H, Kraguljac N, Dhamala E, Homan P, Horga G, Sarpal D, Argyelan M, Gallego J, Cholewa J, Barber A, Kane J, Maholtra A. Replication of a neuroimaging biomarker for striatal dysfunction in psychosis. Res Sq 2023:rs.3.rs-3185688. [PMID: 37609149 PMCID: PMC10441472 DOI: 10.21203/rs.3.rs-3185688/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/24/2023]
Abstract
To bring biomarkers closer to clinical application, they should be generalizable, reliable, and maintain performance within the constraints of routine clinical conditions. The functional striatal abnormalities (FSA), is among the most advanced neuroimaging biomarkers in schizophrenia, trained to discriminate diagnosis, with post-hoc analyses indicating prognostic properties. Here, we attempt to replicate its diagnostic capabilities measured by the area under the curve (AUC) in receiver operator characteristic curves discriminating individuals with psychosis (n=101) from healthy controls (n=51) in the Human Connectome Project for Early Psychosis. We also measured the test-retest (run 1 vs 2) and phase encoding direction (i.e., AP vs PA) reliability with intraclass correlation coefficients (ICC). Additionally, we measured effects of scan length on classification accuracy (i.e., AUCs) and reliability (i.e., ICCs). Finally, we tested the prognostic capability of the FSA by the correlation between baseline scores and symptom improvement over 12 weeks of antipsychotic treatment in a separate cohort (n=97). Similar analyses were conducted for the Yeo networks intrinsic connectivity as a reference. The FSA had good/excellent diagnostic discrimination (AUC=75.4%, 95%CI=67.0%-83.3%; in non-affective psychosis AUC=80.5%, 95%CI=72.1-88.0%, and in affective psychosis AUC=58.7%, 95%CI=44.2-72.0%). Test-retest reliability ranged between ICC=0.48 (95%CI=0.35-0.59) and ICC=0.22 (95%CI=0.06-0.36), which was comparable to that of networks intrinsic connectivity. Phase encoding direction reliability for the FSA was ICC=0.51 (95%CI=0.42-0.59), generally lower than for networks intrinsic connectivity. By increasing scan length from 2 to 10 minutes, diagnostic classification of the FSA increased from AUC=71.7% (95%CI=63.1%-80.3%) to 75.4% (95%CI=67.0%-83.3%) and phase encoding direction reliability from ICC=0.29 (95%CI=0.14-0.43) to ICC=0.51 (95%CI=0.42-0.59). FSA scores did not correlate with symptom improvement. These results reassure that the FSA is a generalizable diagnostic - but not prognostic - biomarker. Given the replicable results of the FSA as a diagnostic biomarker trained on case-control datasets, next the development of prognostic biomarkers should be on treatment-response data.
Collapse
Affiliation(s)
- Jose Rubio
- Institute of Behavioral Science, Feinstein Institutes of Medical Research, Northwell Health
| | - Todd Lencz
- Zucker School of Medicine at Hofstra/Northwell
| | - Hengyi Cao
- The Feinstein Institute for Medical Research
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Rubio JM, Lencz T, Cao H, Kraguljac N, Dhamala E, Homan P, Horga G, Sarpal DK, Argyelan M, Gallego J, Cholewa J, Barber A, Kane J, Malhotra A. Replication of a neuroimaging biomarker for striatal dysfunction in psychosis. medRxiv 2023:2023.07.17.23292779. [PMID: 37503088 PMCID: PMC10371185 DOI: 10.1101/2023.07.17.23292779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/29/2023]
Abstract
To bring biomarkers closer to clinical application, they should be generalizable, reliable, and maintain performance within the constraints of routine clinical conditions. The functional striatal abnormalities (FSA), is among the most advanced neuroimaging biomarkers in schizophrenia, trained to discriminate diagnosis, with post-hoc analyses indicating prognostic properties. Here, we attempt to replicate its diagnostic capabilities measured by the area under the curve (AUC) in receiver operator characteristic curves discriminating individuals with psychosis (n=101) from healthy controls (n=51) in the Human Connectome Project for Early Psychosis. We also measured the test-retest (run 1 vs 2) and phase encoding direction (i.e., AP vs PA) reliability with intraclass correlation coefficients (ICC). Additionally, we measured effects of scan length on classification accuracy (i.e., AUCs) and reliability (i.e., ICCs). Finally, we tested the prognostic capability of the FSA by the correlation between baseline scores and symptom improvement over 12 weeks of antipsychotic treatment in a separate cohort (n=97). Similar analyses were conducted for the Yeo networks intrinsic connectivity as a reference. The FSA had good/excellent diagnostic discrimination (AUC=75.4%, 95%CI=67.0%-83.3%; in non-affective psychosis AUC=80.5%, 95%CI=72.1-88.0%, and in affective psychosis AUC=58.7%, 95%CI=44.2-72.0%). Test-retest reliability ranged between ICC=0.48 (95%CI=0.35-0.59) and ICC=0.22 (95%CI=0.06-0.36), which was comparable to that of networks intrinsic connectivity. Phase encoding direction reliability for the FSA was ICC=0.51 (95%CI=0.42-0.59), generally lower than for networks intrinsic connectivity. By increasing scan length from 2 to 10 minutes, diagnostic classification of the FSA increased from AUC=71.7% (95%CI=63.1%-80.3%) to 75.4% (95%CI=67.0%-83.3%) and phase encoding direction reliability from ICC=0.29 (95%CI=0.14-0.43) to ICC=0.51 (95%CI=0.42-0.59). FSA scores did not correlate with symptom improvement. These results reassure that the FSA is a generalizable diagnostic - but not prognostic - biomarker. Given the replicable results of the FSA as a diagnostic biomarker trained on case-control datasets, next the development of prognostic biomarkers should be on treatment-response data.
Collapse
Affiliation(s)
- Jose M Rubio
- Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, USA
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, USA
- Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, USA
| | - Todd Lencz
- Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, USA
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, USA
- Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, USA
| | - Hengyi Cao
- Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, USA
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, USA
- Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, USA
| | - Nina Kraguljac
- Department of Psychiatry and Behavioral Health, The Ohio State University, Columbus, Ohio
| | - Elvisha Dhamala
- Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, USA
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, USA
- Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, USA
| | - Philipp Homan
- Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatric University Hospital Zurich, University of Zurich, 8032, Zurich, Switzerland
- Neuroscience Center Zurich, University of Zurich and Swiss Federal Institute of Technology Zurich, 8057, Zurich, Switzerland
| | - Guillermo Horga
- Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, USA
| | - Deepak K Sarpal
- Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Miklos Argyelan
- Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, USA
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, USA
- Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, USA
| | - Juan Gallego
- Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, USA
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, USA
- Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, USA
| | - John Cholewa
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, USA
- Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, USA
| | - Anita Barber
- Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, USA
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, USA
- Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, USA
| | - John Kane
- Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, USA
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, USA
- Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, USA
| | - Anil Malhotra
- Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, USA
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, USA
- Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, USA
| |
Collapse
|
8
|
Ji JL, Lencz T, Gallego J, Neufeld N, Voineskos A, Malhotra A, Anticevic A. Informing individualized multi-scale neural signatures of clozapine response in patients with treatment-refractory schizophrenia. medRxiv 2023:2023.03.10.23286854. [PMID: 36993630 PMCID: PMC10055439 DOI: 10.1101/2023.03.10.23286854] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/19/2023]
Abstract
Clozapine is currently the only antipsychotic with demonstrated efficacy in treatment-refractory schizophrenia (TRS). However, response to clozapine differs widely between TRS patients, and there are no available clinical or neural predictive indicators that could be used to increase or accelerate the use of clozapine in patients who stand to benefit. Furthermore, it remains unclear how the neuropharmacology of clozapine contributes to its therapeutic effects. Identifying the mechanisms underlying clozapine's therapeutic effects across domains of symptomatology could be crucial for development of new optimized therapies for TRS. Here, we present results from a prospective neuroimaging study that quantitatively related heterogeneous patterns of clinical clozapine response to neural functional connectivity at baseline. We show that we can reliably capture specific dimensions of clozapine clinical response by quantifying the full variation across item-level clinical scales, and that these dimensions can be mapped to neural features that are sensitive to clozapine-induced symptom change. Thus, these features may act as "failure modes" that can provide an early indication of treatment (non-)responsiveness. Lastly, we related the response-relevant neural maps to spatial expression profiles of genes coding for receptors implicated in clozapine's pharmacology, demonstrating that distinct dimensions of clozapine symptom-informed neural features may be associated with specific receptor targets. Collectively, this study informs prognostic neuro-behavioral measures for clozapine as a more optimal treatment for selected patients with TRS. We provide support for the identification of neuro-behavioral targets linked to pharmacological efficacy that can be further developed to inform optimal early treatment decisions in schizophrenia.
Collapse
|
9
|
Jiménez-Fonseca P, Sastre J, García-Alfonso P, Gómez-España MA, Salud A, Gil S, Rivera F, Reina JJ, Quintero G, Valladares-Ayerbes M, Safont MJ, La Casta A, Robles-Díaz L, García-Paredes B, López López R, Guillot M, Gallego J, Alonso-Orduña V, Diaz-Rubio E, Aranda E. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials. Clin Colorectal Cancer 2023; 22:222-230. [PMID: 36944559 DOI: 10.1016/j.clcc.2023.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 01/30/2023] [Accepted: 02/10/2023] [Indexed: 02/25/2023]
Abstract
BACKGROUND The bCTC count is a well-established prognostic biomarker in mCRC, as well as in other tumor types. The aim of this analysis was to evaluate the prognostic/predictive role of the bCTC count (≥3 vs. <3) in previously untreated mCRC. PATIENTS AND METHODS The study involved 589 untreated mCRC patients included in the intention-to-treat population of 2 randomized clinical trials (phase III VISNU-1 [NCT01640405] and phase II VISNU-2 [NCT01640444] studies). RESULTS Of the 589 patients, 349 (59.2%) had bCTC≥3 and 240 (40.7%) had bCTC<3. Multivariate analysis showed that the bCTC count is an independent prognostic factor for overall survival (OS) (HR 0.59, 95% CI 0.48-0.72; P = 0.000) and potential for progression-free survival (PFS) (P = 0.0549). Median OS was 32.9 and 19.5 months in patients with bCTC<3 and bCTC≥3 (P <0.001), respectively. This effect was also observed comparing OS in RASwt patients from both studies. Other prognostic factors were: ECOG-PS, primary tumor site, number of metastatic sites and surgery of the primary tumor. Median OS was lower for patients treated with anti-VEGF versus anti-EGFR (22.3 vs. 33.3 months, P <0.0001) while there were no significant differences in PFS according to the targeted treatment received. CONCLUSION This post-hoc analysis of 2 randomized studies confirms the poor prognosis of patients with bCTC≥3 but this is not associated with other adverse independent prognostic factors such as RAS/BRAF mutations.
Collapse
Affiliation(s)
- P Jiménez-Fonseca
- Department of Medical Oncology. Hospital Universitario Central de Asturias, ISPA, Oviedo, 33011, Spain.
| | - J Sastre
- Department of Medical Oncology. Hospital Clínico San Carlos. Instituto de Investigación Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, 28040, Spain
| | - P García-Alfonso
- Department of Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid, 28007, Spain
| | - M A Gómez-España
- Department of Medical Oncology. Hospital Universitario Reina Sofía, IMIBIC, Universidad de Córdoba, CIBERONC, Instituto de Salud Carlos III, Córdoba, 14004, Spain
| | - A Salud
- Department of Medical Oncology, Hospital Universitario Arnau de Vilanova, Lérida, 25198, Spain
| | - S Gil
- Department of Medical Oncology. Hospital Universitario Regional y Virgen de la Victoria, IBIMA, Málaga, 29010, Spain
| | - F Rivera
- Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, 39008, Spain
| | - J J Reina
- Department of Medical Oncology, Complejo Hospitalario Virgen de la Macarena, Sevilla, 41009, Spain
| | - G Quintero
- Department of Medical Oncology, Hospital Universitario Lucus Augusti, Lugo, 27003, Spain
| | - M Valladares-Ayerbes
- Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Sevilla, 41013, Spain
| | - M J Safont
- Department of Medical Oncology, Hospital General Universitario de Valencia, CIBERONC, Universidad de Valencia, Valencia, 46014, Spain
| | - A La Casta
- Department of Medical Oncology, Hospital de Donostia, Guipúzcoa, 20014, Spain
| | - L Robles-Díaz
- Department of Medical Oncology. Hospital Universitario 12 de Octubre, Madrid, 28041, Spain
| | - B García-Paredes
- Department of Medical Oncology. Hospital Clínico San Carlos. Instituto de Investigación Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, 28040, Spain
| | - R López López
- Department of Medical Oncology and Translational Medical Oncology Group. Hospital Universitario Santiago de Compostela and Health Research Institute (IDIS), CIBERONC, Santiago de Compostela, 15706, Spain
| | - M Guillot
- Department of Medical Oncology. Hospital Universitario Son Espases, Palma de Mallorca, 07120, Spain
| | - J Gallego
- Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, 03203, Spain
| | - V Alonso-Orduña
- Department of Medical Oncology, Hospital Universitario Miguel Servet. Instituto de Investigación Sanitaria de Aragón (IISA), Zaragoza, 50009, Spain
| | - E Diaz-Rubio
- Department of Medical Oncology. Hospital Clínico San Carlos. Instituto de Investigación Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, 28040, Spain
| | - E Aranda
- Department of Medical Oncology. Hospital Universitario Reina Sofía, IMIBIC, Universidad de Córdoba, CIBERONC, Instituto de Salud Carlos III, Córdoba, 14004, Spain
| | | |
Collapse
|
10
|
Cortés D, Maldonado D, Gallego J, Charpak N, Tessier R, Ruiz JG, Hernandez JT, Uriza F, Pico J. Comparing long-term educational effects of two early childhood health interventions. J Health Econ 2022; 86:102693. [PMID: 36323186 DOI: 10.1016/j.jhealeco.2022.102693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/24/2021] [Revised: 09/20/2022] [Accepted: 10/07/2022] [Indexed: 06/16/2023]
Abstract
We compare the educational effects of two medical protocols that mitigate long-term consequences of prematurity or low birth weight. The two protocols are Traditional Care (TC), which uses incubators, and Kangaroo Mother Care (KMC) which replaces incubators for 24-hour skin-to-skin contact between newborns and caregivers. We concentrate on educational outcomes addressing contradictory results in previous contributions. We use a randomized controlled trial implemented in 1993 that randomly assigned children to either TC or KMC. OLS results suggest that KMC children spent more time in preschool, had fewer temporary school absences, and showed lower math test scores. Both groups observed similar effects on high-school graduation and language test scores. We correct for attrition, small sample, and multiple outcomes. Effects on preschool attendance and school absenteeism are robust, particularly for more vulnerable infants (birth weight ≤ 1,800 g). The other effects lose statistical significance due to multiple outcome testing or attrition corrections.
Collapse
Affiliation(s)
- Darwin Cortés
- School of Economics, Universidad del Rosario, Colombia.
| | | | - Juan Gallego
- School of Economics, Universidad del Rosario, Colombia
| | | | | | - Juan Gabriel Ruiz
- Department of Medical and Population Health Sciences Research, Herber Wertheim, Florida International University, United States of America
| | | | - Felipe Uriza
- Hospital San Ignacio, Universidad Javeriana, Colombia
| | - Julieth Pico
- School of Economics, Universidad del Rosario, Colombia
| |
Collapse
|
11
|
Franesqui MA, Yepes J, Gallego J. Mechanical performance under dynamic loading of rubberized asphalt mixtures with highly-porous vesicular aggregate. Sci Rep 2022; 12:19973. [DOI: 10.1038/s41598-022-24197-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Accepted: 11/11/2022] [Indexed: 11/20/2022] Open
Abstract
AbstractIn volcanic regions, the use of certain abundant aggregates of scoriaceous nature with high porosity to manufacture bituminous paving mixtures is a major problem due to the excessive heterogeneity, absorption and limited strength of these aggregates. Consequently, the properties of the mixtures often do not meet technical specifications. The aim of this research is to study the improvement of the mechanical performance of asphalt mixtures with these residual volcanic aggregates by using binders modified with rubber from end-of-life tyres, since environmental and economic requirements make it necessary to reuse both types of waste. Laboratory studies determining the compactability, dynamic stiffness, fatigue resistance and elastic constants have made it possible to characterise the mechanical performance of these mixtures during production and in service, and to compare them with conventional mixtures. It was found that the use of tyre rubber modified bitumen makes compaction somewhat more difficult, but reduces the particle size degradation of the porous aggregates and improves the mixture performance and durability, showing higher stiffness moduli and increased resistance to fatigue.
Collapse
|
12
|
Alsop E, Meechoovet B, Kitchen R, Sweeney T, Beach TG, Serrano GE, Hutchins E, Ghiran I, Reiman R, Syring M, Hsieh M, Courtright-Lim A, Valkov N, Whitsett TG, Rakela J, Pockros P, Rozowsky J, Gallego J, Huentelman MJ, Shah R, Nakaji P, Kalani MYS, Laurent L, Das S, Van Keuren-Jensen K. A Novel Tissue Atlas and Online Tool for the Interrogation of Small RNA Expression in Human Tissues and Biofluids. Front Cell Dev Biol 2022; 10:804164. [PMID: 35317387 PMCID: PMC8934391 DOI: 10.3389/fcell.2022.804164] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2021] [Accepted: 01/28/2022] [Indexed: 12/20/2022] Open
Abstract
One promising goal for utilizing the molecular information circulating in biofluids is the discovery of clinically useful biomarkers. Extracellular RNAs (exRNAs) are one of the most diverse classes of molecular cargo, easily assayed by sequencing and with expressions that rapidly change in response to subject status. Despite diverse exRNA cargo, most evaluations from biofluids have focused on small RNA sequencing and analysis, specifically on microRNAs (miRNAs). Another goal of characterizing circulating molecular information, is to correlate expression to injuries associated with specific tissues of origin. Biomarker candidates are often described as being specific, enriched in a particular tissue or associated with a disease process. Likewise, miRNA data is often reported to be specific, enriched for a tissue, without rigorous testing to support the claim. Here we provide a tissue atlas of small RNAs from 30 different tissues and three different blood cell types. We analyzed the tissues for enrichment of small RNA sequences and assessed their expression in biofluids: plasma, cerebrospinal fluid, urine, and saliva. We employed published data sets representing physiological (resting vs. acute exercise) and pathologic states (early- vs. late-stage liver fibrosis, and differential subtypes of stroke) to determine differential tissue-enriched small RNAs. We also developed an online tool that provides information about exRNA sequences found in different biofluids and tissues. The data can be used to better understand the various types of small RNA sequences in different tissues as well as their potential release into biofluids, which should help in the validation or design of biomarker studies.
Collapse
Affiliation(s)
- Eric Alsop
- Neurogenomics Division, The Translational Genomics Research Institute, Phoenix, AZ, United States
| | - Bessie Meechoovet
- Neurogenomics Division, The Translational Genomics Research Institute, Phoenix, AZ, United States
| | - Robert Kitchen
- Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States
| | - Thadryan Sweeney
- Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States
| | - Thomas G. Beach
- Banner Sun Health Research Institute, Sun City, AZ, United States
| | - Geidy E. Serrano
- Banner Sun Health Research Institute, Sun City, AZ, United States
| | - Elizabeth Hutchins
- Neurogenomics Division, The Translational Genomics Research Institute, Phoenix, AZ, United States
| | - Ionita Ghiran
- Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States
| | - Rebecca Reiman
- Neurogenomics Division, The Translational Genomics Research Institute, Phoenix, AZ, United States
| | - Michael Syring
- Neurogenomics Division, The Translational Genomics Research Institute, Phoenix, AZ, United States
| | - Michael Hsieh
- Neurogenomics Division, The Translational Genomics Research Institute, Phoenix, AZ, United States
| | - Amanda Courtright-Lim
- Neurogenomics Division, The Translational Genomics Research Institute, Phoenix, AZ, United States
| | - Nedyalka Valkov
- Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States
| | - Timothy G. Whitsett
- Neurogenomics Division, The Translational Genomics Research Institute, Phoenix, AZ, United States
| | | | - Paul Pockros
- Division of Gastroenterology/Hepatology, Scripps Clinic, La Jolla, CA, United States
| | - Joel Rozowsky
- Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT, United States
| | - Juan Gallego
- Institute for Behavioral Science, The Feinstein Institute for Medical Research, Manhasset, NY, United States
- Division of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, NY, United States
- Department of Psychiatry, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, United States
| | - Matthew J. Huentelman
- Neurogenomics Division, The Translational Genomics Research Institute, Phoenix, AZ, United States
| | - Ravi Shah
- Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States
| | - Peter Nakaji
- Department of Neurosurgery, Banner Health, Phoenix, AZ, United States
| | - M. Yashar S. Kalani
- Department of Neurosurgery, St. John Medical Center, Tulsa, OK, United States
| | - Louise Laurent
- Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, San Diego, CA, United States
| | - Saumya Das
- Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States
| | | |
Collapse
|
13
|
Vizcarra P, Gallego J, Sobrino C, Sifuentes WA, Vivancos MJ, Casado JL. [Prevalence of low bone mass in individuals with HIV infection]. Med Clin (Barc) 2021; 157:234-237. [PMID: 33059939 DOI: 10.1016/j.medcli.2020.06.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Revised: 06/08/2020] [Accepted: 06/12/2020] [Indexed: 10/23/2022]
Abstract
BACKGROUND AND AIMS There are no population data on bone mass in individuals with HIV in Spain, adjusted for age and sex. MATERIALS AND METHODS Bone mineral density (BMD) data were obtained by dual X-ray absorptiometry in a cohort of individuals with HIV infection compared with cohort data from the general population in Spain and the United States of America. RESULTS Of 928 individuals (mean 46 years, 25% women), the prevalence of osteoporosis in the lumbar spine/femoral neck was 18%/5% in men, and 17%/10% in women, respectively. The rate increased from the age of 40 in men and from 50 in women (osteoporosis in 20% and 27%, respectively). BMD was lower than that observed in the general population in almost all age groups (mean, -6%; between 0%-11% lower compared to the Spanish cohort, and -8%; between 0%-14% lower than the American cohort). CONCLUSIONS Our cohort of individuals with HIV had a lower BMD in all age groups after adjustment for age and sex, compared with the general population. This fact must be considered when making recommendations.
Collapse
Affiliation(s)
- Pilar Vizcarra
- Servicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal, Madrid, España.
| | - Juan Gallego
- Servicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal, Madrid, España
| | - Cristina Sobrino
- Servicio de Reumatología, Hospital Universitario Ramón y Cajal, Madrid, España
| | - Walter A Sifuentes
- Servicio de Reumatología, Hospital Universitario Ramón y Cajal, Madrid, España
| | - María J Vivancos
- Servicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal, Madrid, España
| | - José L Casado
- Servicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal, Madrid, España
| |
Collapse
|
14
|
Grande E, Garcia-Carbonero R, Teule A, Benavent Viñuales M, Jimenez-Fonseca P, Molina-Cerrillo J, López C, Custodio A, Hierro C, Gallego J, Alonso V, Carmona-Bayonas A, Llanos M, Sevilla I, Hernando J, Lista F, Antón Pascual B, Ruffinelli J, Gallego Jiménez I, Capdevila J. 575TiP Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.710] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
15
|
Martinez Lago N, Carmona-Bayonas A, Pieras Lopez A, Ramchandani A, Longo F, Martin Carnicero A, Granja Ortega M, Calvo A, Hernandez R, Castro Unanua N, Assaf J, Azkarate A, Hernandez-Perez C, Camara J, Saurí T, Custodio A, Cano J, Fernandez Montes A, Martinez de Castro E, Gallego J. 1394P Frequentist and Bayesian analysis of second line treatment effectiveness in AGAMENON-SEOM gastric cancer registry. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
16
|
Ramanantsoa N, Bourgeois T, Madani A, Sizun E, Ringot M, Delclaux C, Dauger S, d’Ortho M, Matrot B, Gallego J. Augmentation de la réponse ventilatoire au COD chez la souris mutante conditionnelle Phox2b27Ala/+ par une action pharmacologique. Rev Mal Respir 2021. [DOI: 10.1016/j.rmr.2021.02.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
17
|
Flores G, Gallego J, Miranda L, Marcobal JR. Influence of the Compaction Method in the Volumetric Design of Cold Recycled Mixtures with Emulsion. Materials (Basel) 2021; 14:ma14051309. [PMID: 33803311 PMCID: PMC7967114 DOI: 10.3390/ma14051309] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Revised: 02/28/2021] [Accepted: 03/05/2021] [Indexed: 11/17/2022]
Abstract
Compaction of cold asphalt mixtures is a subject that has not been thoroughly studied, and, for this reason, requires new efforts from researchers to have a better understanding. Unlike hot mixtures, cold mixtures and mainly recycled mixtures require specific considerations for compaction. There is a lack of consensus about the methodology to select the optimum premix water and emulsion contents. In the absence of specific regulations, the use of soil tests or hot mixtures procedures is common. For these reasons, this investigation’s main goal was to evaluate two compaction methods used to design cold recycled mixtures with emulsion: the modified Proctor procedure and the gyratory compaction. It was concluded that both methods could be useful to study compactability since consistent results were obtained by applying the maximum bulk density criterion. However, the higher bulk densities achieved, the smaller specimens used, and the suitability of the gyratory specimens to be later tested for mechanical properties make them preferable to the modified Proctor samples. A new approach has been proposed using iso-density lines on dual-axis premix water content-emulsion content graphs that facilitates the study of the influence on compactability of these two factors combined. These contributions can alleviate the laboratory works during the design of cold recycled asphalt mixtures and contribute to a more in-depth knowledge of the combined effect of premix water and emulsion contents on the compactability of cold recycled mixtures with emulsion.
Collapse
Affiliation(s)
- Guillermo Flores
- Departamento de Ingeniería del Transporte, Territorio y Urbanismo, Universidad Politécnica de Madrid, 28040 Madrid, Spain; (G.F.); (J.R.M.)
| | - Juan Gallego
- Departamento de Ingeniería del Transporte, Territorio y Urbanismo, Universidad Politécnica de Madrid, 28040 Madrid, Spain; (G.F.); (J.R.M.)
- Correspondence: ; Tel.: +34-910674219
| | | | - José Ramón Marcobal
- Departamento de Ingeniería del Transporte, Territorio y Urbanismo, Universidad Politécnica de Madrid, 28040 Madrid, Spain; (G.F.); (J.R.M.)
- Sacyr, 28027 Madrid, Spain
| |
Collapse
|
18
|
Vancutsem C, Achard F, Pekel JF, Vieilledent G, Carboni S, Simonetti D, Gallego J, Aragão LEOC, Nasi R. Long-term (1990-2019) monitoring of forest cover changes in the humid tropics. Sci Adv 2021; 7:7/10/eabe1603. [PMID: 33674308 PMCID: PMC7935368 DOI: 10.1126/sciadv.abe1603] [Citation(s) in RCA: 47] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/06/2020] [Accepted: 01/21/2021] [Indexed: 05/22/2023]
Abstract
Accurate characterization of tropical moist forest changes is needed to support conservation policies and to quantify their contribution to global carbon fluxes more effectively. We document, at pantropical scale, the extent and changes (degradation, deforestation, and recovery) of these forests over the past three decades. We estimate that 17% of tropical moist forests have disappeared since 1990 with a remaining area of 1071 million hectares in 2019, from which 10% are degraded. Our study underlines the importance of the degradation process in these ecosystems, in particular, as a precursor of deforestation, and in the recent increase in tropical moist forest disturbances (natural and anthropogenic degradation or deforestation). Without a reduction of the present disturbance rates, undisturbed forests will disappear entirely in large tropical humid regions by 2050. Our study suggests that reinforcing actions are needed to prevent the initial degradation that leads to forest clearance in 45% of the cases.
Collapse
Affiliation(s)
- C Vancutsem
- European Commission, Joint Research Centre, Via E. Fermi 2749-TP 261, I-21027 Ispra (VA), Italy.
| | - F Achard
- European Commission, Joint Research Centre, Via E. Fermi 2749-TP 261, I-21027 Ispra (VA), Italy
| | - J-F Pekel
- European Commission, Joint Research Centre, Via E. Fermi 2749-TP 261, I-21027 Ispra (VA), Italy
| | - G Vieilledent
- European Commission, Joint Research Centre, Via E. Fermi 2749-TP 261, I-21027 Ispra (VA), Italy
- CIRAD, UMR AMAP, F-34398 Montpellier, France
- CIRAD, Forêts et Sociétés, F-34398 Montpellier, France
- AMAP, Univ Montpellier, CIRAD, CNRS, INRAE, IRD, Montpellier, France
| | - S Carboni
- GFT Italia Srl, Via Sile 18, Milan, Italy
| | - D Simonetti
- European Commission, Joint Research Centre, Via E. Fermi 2749-TP 261, I-21027 Ispra (VA), Italy
| | - J Gallego
- European Commission, Joint Research Centre, Via E. Fermi 2749-TP 261, I-21027 Ispra (VA), Italy
| | - L E O C Aragão
- National Institute for Space Research (INPE), São José dos Campos, Brazil
| | - R Nasi
- Center for International Forestry Research (CIFOR), Bogor, Indonesia
| |
Collapse
|
19
|
Seguí E, Alonso-Orduna V, Sesma A, Martin-Richard M, Salud A, Fernández-Montes A, Fernández-Martos C, Ruiz-Casado A, Gallego J, Aparicio J, Gálvez E, Manzano H, Alcaide-Garcia J, Gallego R, Falco E, Esposito F, Oliveres H, Torres F, Feliu J, Maurel J. 471P Identification and validation of a new prognostic score in metastatic colorectal cancer (mCRC): GEMCAD score. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
20
|
Vera R, Salgado M, Safont MJ, Gallego J, González E, Élez E, Aranda E. Controversies in the treatment of RAS wild-type metastatic colorectal cancer. Clin Transl Oncol 2020; 23:827-839. [PMID: 32789773 PMCID: PMC7979622 DOI: 10.1007/s12094-020-02475-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2020] [Accepted: 08/03/2020] [Indexed: 01/05/2023]
Abstract
Objective To provide guidance for the management of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in daily practice. Methods Nominal group and Delphi techniques were used. A steering committee of seven experts analyzed the current management of RAS wt mCRC, through which they identified controversies, critically analyzed the available evidence, and formulated several guiding statements for clinicians. Subsequently, a group of 30 experts (the expert panel) was selected to test agreement with the statements, through two Delphi rounds. The following response categories were established in both rounds: 1 = totally agree, 2 = basically agree, 3 = basically disagree, 4 = totally disagree. Agreement was defined if ≥ 75% of answers were in categories 1 and 2 (consensus with the agreement) or 3 and 4 (consensus with the disagreement). Results Overall, 71 statements were proposed, which incorporated the following areas: (1) overarching principles; (2) tumor location; (3) triplets; (4) maintenance; (5) second-line and beyond treatments; (6) Rechallenge and liquid biopsy. After the two Delphi rounds, only six statements maintained a lack of clear consensus. Conclusions This document aims to describe the expert’s attitude when dealing with several common clinical questions regarding patients with RAS wt mCRC. Electronic supplementary material The online version of this article (10.1007/s12094-020-02475-8) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- R Vera
- Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - M Salgado
- Medical Oncology Department, Complejo Hospitalario Universitario de Ourense, Ourense, Spain
| | - M J Safont
- Medical Oncology Department, Hospital General Universitario de Valencia, Valencia, Spain
| | - J Gallego
- Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain
| | - E González
- Medical Oncology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain
| | - E Élez
- Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - E Aranda
- Medical Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Hospital Reina Sofía, University of Córdoba, Av. Menendez Pidal, s/n, 14004, Córdoba, Spain.
| |
Collapse
|
21
|
Vizcarra P, Gallego J, Vivancos MJ, Sifuentes WA, Llop M, Casado JL. Evaluation of the fracture risk assessment tool for determining bone disease and the impact of secondary causes of osteoporosis in people living with HIV. HIV Res Clin Pract 2020; 21:63-71. [PMID: 32698706 DOI: 10.1080/25787489.2020.1794438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
BACKGROUND Among HIV-infected individuals, screening for bone disease is encouraged to assess reversible risk factors and plan therapeutic interventions. OBJECTIVE We assessed the usefulness of Fracture Risk Assessment (FRAX) tool to identify candidates for dual X-ray absorptiometry (DXA) scan, or individuals with bone loss progression. We further explored how secondary causes of osteoporosis are reflected on FRAX. METHODS Longitudinal study of 217 consecutive individuals (mean, 45.8 years, 24% females) included after DXA scan. FRAX was calculated without/with femoral neck bone mineral density (BMD), checking the box of "secondary osteoporosis" for all the individuals. RESULTS Low BMD was observed in 133/217 (61%) individuals, of whom 98.5% had not been selected as candidates for DXA by current FRAX thresholds. Specifically, 23% of individuals aged <50 had low BMD but none was candidate for DXA. Adding BMD data, FRAX results increased by 50-100%, with 2/217 individuals (1%) above the thresholds. Classical and HIV-related secondary causes of osteoporosis (observed in 98% overall) correlated with low BMD, modifying significantly FRAX results (HCV coinfection, +124%; longer time of HIV infection, +93%; longer time on antiretroviral therapy, +147%; tenofovir exposure +36%). Individuals with lower BMD and higher FRAX results at inclusion had less bone decline in a follow-up DXA after a median of 3.5 years. CONCLUSIONS Currently recommended FRAX thresholds are not useful to select candidates for DXA scan, which could delay its performance in a population with a high prevalence of secondary factors for low BMD. Classical and HIV-related factors alter BMD and fracture risk estimation.
Collapse
Affiliation(s)
- Pilar Vizcarra
- Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
| | - Juan Gallego
- Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
| | - María J Vivancos
- Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
| | - Walter A Sifuentes
- Department of Rheumatology, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
| | - María Llop
- Department of Rheumatology, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
| | - José L Casado
- Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
| |
Collapse
|
22
|
Lizárraga JM, Gallego J. Self-Healing Analysis of Half-Warm Asphalt Mixes Containing Electric Arc Furnace (EAF) Slag and Reclaimed Asphalt Pavement (RAP) using a Novel Thermomechanical Healing Treatment. Materials (Basel) 2020; 13:E2502. [PMID: 32486246 PMCID: PMC7321439 DOI: 10.3390/ma13112502] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/26/2020] [Revised: 05/13/2020] [Accepted: 05/25/2020] [Indexed: 11/16/2022]
Abstract
Nowadays, the self-healing of asphalt pavements promoted by microwave radiation heating energy is gaining attention and strength in the scientific community. However, most of these studies are only conceptual and, thus, remain shrouded in uncertainty regarding technology development, economy, and application effect. Therefore, there are several efforts underway to offer more effective assisted healing treatments that are capable of overcoming such uncertainties. This paper aims to assess and quantify the healing performance rates (HR) of half-warm recycled asphalt (HWRA) mixtures containing electric arc furnace (EAF) slag and total recycled asphalt pavement (RAP) rates. To this end, a novel assisted thermomechanical healing treatment (i.e., a recompaction-based technique and microwave heating energy) was put forward to promote the potential healing effect of this treatment on the mechanical properties of the asphalt mixtures. In order to do this, three microwave heating temperatures (25 °C, 60 °C, and 80 °C) and three mechanical recompaction levels (0, 25, and 50 gyrations) were selected. After that, the healing performance rates (%, HR) of the asphalt mixtures were calculated by repeated indirect tensile strength (ITS) and indirect tensile stiffness modulus (ITSM). The results indicated that the 8% EAF slag mixture was found to provide significant microwave heating energy savings by up to 69% compared with the benchmark 100% RAP mixture, and, at the same time, it experienced a remarkable stiffness recovery response of 140% of the initial mechanical properties. These findings encourage greater confidence in promoting this innovative thermomechanical-based healing treatment for in-situ surface course asphalt mixtures of road pavements.
Collapse
Affiliation(s)
- José Manuel Lizárraga
- Departamento de Ingeniería del Transporte, Urbanismo y Territorio, Universidad Politécnica de Madrid, 28040 Madrid, Spain;
| | | |
Collapse
|
23
|
Martín-Richard M, Carmona-Bayonas A, Custodio AB, Gallego J, Jiménez-Fonseca P, Reina JJ, Richart P, Rivera F, Alsina M, Sastre J. SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019). Clin Transl Oncol 2020; 22:236-244. [PMID: 31989475 DOI: 10.1007/s12094-019-02259-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2019] [Accepted: 11/30/2019] [Indexed: 02/07/2023]
Abstract
Gastric cancer (GC) is the fifth most common cancer worldwide with a varied geographic distribution and an aggressive behavior. In Spain, it represents the sixth cause of cancer death. In Western countries, the incidence is decreasing slightly, with an increase in gastroesophageal junction adenocarcinoma (GEJA), a different entity that we separate specifically in the guideline. Molecular biology advances have been done recently, but do not yet lead to the choice in treatment approach except in advanced disease with overexpression of HER2. Endoscopic resection in very early stage, perioperative chemotherapy in locally advanced tumors and preliminary immune therapy resulting in advanced disease are the main treatment innovations in the GC/GEJA treatment. We describe the different evidences and recommendations following the statements of the American College of Physicians.
Collapse
Affiliation(s)
- M Martín-Richard
- Medical Oncology Department, Hospital de la Santa Creu I Sant Pau, Sant Antoni Maria Claret, 167, 08025, Barcelona, Spain.
| | - A Carmona-Bayonas
- Medical Oncology Department, Hospital J.M. Morales Meseguer, Murcia, Spain
| | - Ana B Custodio
- Medical Oncology Department, Hospital Universitario La Paz, Centro de Investigación Biomédica en Red Cáncer, CB16/12/00398, Madrid, Spain
| | - J Gallego
- Medical Oncology Department, Hospital General Universitario de Elche y Vega Baja, Alicante, Spain
| | - P Jiménez-Fonseca
- Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - J J Reina
- Medical Oncology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain
| | - P Richart
- Medical Oncology Department, Hospital Universitari I Politècnic la Fe, Valencia, Spain
| | - F Rivera
- Medical Oncology Department, Hospital Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - M Alsina
- Medical Oncology Department, Hospital Universitario Vall D'Hebron, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - J Sastre
- Medical Oncology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain
| |
Collapse
|
24
|
Gallego J, Rodríguez-Alloza AM, Saiz-Rodríguez L. Evaluation of Warm Rubberized Stone Mastic Asphalt Mixtures through the Marshall and Gyratory Compactors. Materials (Basel) 2020; 13:ma13020265. [PMID: 31936118 PMCID: PMC7014020 DOI: 10.3390/ma13020265] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/24/2019] [Revised: 12/10/2019] [Accepted: 12/21/2019] [Indexed: 06/10/2023]
Abstract
Stone mastic asphalt (SMA) mixtures exhibit excellent behaviour; they are highly resistant to reflective cracking and permanent deformation, as well as providing the wearing surface with an optimal texture. However, the production and compaction temperatures are similar to conventional mixtures, which means that there is a significant consumption of energy, as well as greenhouse gas emissions. Warm mix asphalt (WMA) technology, which has been developed over the last few years, might allow lower temperatures without compromising the mechanical behaviour of the mixtures. Also, over the last few decades, rubberized asphalt has proved to be effective in improving the performance and being environmentally suitable, but it requires higher production temperatures than conventional mixtures. In this study, several tests were performed to evaluate the effect of a chemical WMA additive on the compactability and water sensitivity of rubberized SMA mixtures with both the Marshall and the gyratory compactor. The investigation has shown that the gyratory compactor is more suitable for studying compactability and the water sensitivity of rubberized SMA with WMA additives.
Collapse
Affiliation(s)
- Juan Gallego
- Departamento de Ingeniería del Transporte, Urbanismo y Territorio, Universidad Politécnica de Madrid (UPM), C/ Profesor Aranguren 3, 28040 Madrid, Spain;
| | - Ana María Rodríguez-Alloza
- Departamento de Ingeniería Civil: Construcción, Infraestructura y Transporte, Universidad Politécnica de Madrid (UPM), C/ Alfonso XII 3, 28014 Madrid, Spain
| | | |
Collapse
|
25
|
Garrett M, Ahmed AO, Athineos C, Cruz L, Harris K, Del Pozzo J, Forster V, Gallego J. Identifying psychological resistances to using logic in cognitive-behavioral therapy for psychosis (CBTp) that limit successful outcomes for patients. Psychosis 2019. [DOI: 10.1080/17522439.2019.1632377] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- Michael Garrett
- Department of Psychiatry, SUNY Downstate Medical Center, Brooklyn, NY, USA
| | - Anthony O. Ahmed
- Department of Psychiatry, Weill Cornell Medicine, NewYork-Presbyterian/Westchester, White Plains, NY, USA
| | - Christina Athineos
- Department of Psychiatry, Weill Cornell Medicine, NewYork-Presbyterian/Westchester, White Plains, NY, USA
| | - Lisa Cruz
- Department of Psychiatry, Weill Cornell Medicine, NewYork-Presbyterian/Westchester, White Plains, NY, USA
| | - Kelly Harris
- Department of Psychiatry, Weill Cornell Medicine, NewYork-Presbyterian/Westchester, White Plains, NY, USA
| | - Jill Del Pozzo
- Department of Psychiatry, Weill Cornell Medicine, NewYork-Presbyterian/Westchester, White Plains, NY, USA
| | - Victoria Forster
- Department of Psychiatry, Weill Cornell Medicine, NewYork-Presbyterian/Westchester, White Plains, NY, USA
| | - Juan Gallego
- Department of Psychiatry, Weill Cornell Medicine, NewYork-Presbyterian/Westchester, White Plains, NY, USA
| |
Collapse
|
26
|
Laspidea V, Puigdelloses M, García-Moure M, Iñigo-Marco I, Gallego J, Patiño-García A, Fueyo J, Gomez-Manzano C, Alonso MM. P06.01 Delta24-ACT oncolytic adenovirus as a therapeutic approach for DIPG. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
Diffuse intrinsic pontine glioma (DIPG) is an aggressive brain tumor, being the leading cause of pediatric death caused by cancer. We previously showed that administration of the oncolytic virus Delta-24-RGD to DIPG murine models was safe and led to an increase in the median survival of these animals. However, not all the animals responded, underscoring the need to improve this therapy. In order to increase the antitumoral effect of the virus, we have engineered Delta-24-RGD with the costimulatory ligand 4-1BBL (Delta24-ACT). 4-1BB is a costimulatory receptor that promotes the survival and expansion of activated T cells, and the generation and maintenance of memory CD8+ T cells. In this project, we evaluated the oncolytic effect of Delta24-ACT and the antitumor immune response in DIPG murine models.
MATERIALS AND METHODS
We use the NP53 and XFM murine DIPG cell lines. Flow cytometry was used to assess cell infectivity and ligand expression. We analyzed viral replication using a method based in hexon detection, and viral cytotoxic effect using the MTS assay. For immunogenic cell death analysis, we measured ATP secretion by a luminometric assay and calreticulin location by flow cytometry and immunofluorescence. For in vivo studies, cells and virus were injected in the pons of the mice, using the screw-guided system.
RESULTS
In vitro, Delta24-ACT was able to infect and induce cell death in a dose-dependent manner in murine DIPG cell lines. In addition, Delta24-ACT was able to replicate in these tumor cells and to express viral proteins. Moreover, infected cells expressed 41BBL in their membranes. Delta24-ACT could induce immunogenic cell death due to an increased secretion of ATP and calreticulin translocation to the membrane of infected cells (in no-infected cells it located in the ER), DAMPs that can trigger the immune response activation. In vivo, Delta24-ACT demonstrated to be safe in all the tested doses and was able to induce a significant increase in the median survival of the treated animals. Moreover, long-term survivors display immunological memory.
CONCLUSIONS
Delta24-ACT treatment led to antitumoral effect in DIPG murine cell lines in vitro. Of significance, we have demonstrated that in vivo administration of Delta24-ACT is safe and results in an enhanced antitumor effect. Future in vivo studies will explore the underlying immune mechanism of the virus.
Collapse
Affiliation(s)
| | | | | | | | - J Gallego
- University of Navarra, Pamplona, Spain
| | | | - J Fueyo
- UT MD Anderson Cancer Center, Houston, TX, United States
| | | | | |
Collapse
|
27
|
Shafritz KM, Ikuta T, Greene A, Robinson DG, Gallego J, Lencz T, DeRosse P, Kingsley PB, Szeszko PR. Frontal lobe functioning during a simple response conflict task in first-episode psychosis and its relationship to treatment response. Brain Imaging Behav 2019; 13:541-553. [PMID: 29744804 DOI: 10.1007/s11682-018-9876-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Prior functional magnetic resonance imaging (fMRI) studies have investigated the neural mechanisms underlying cognitive control in patients with psychosis with findings of both hypo- and hyperfrontality. One factor that may contribute to inconsistent findings is the use of complex and polyfactorial tasks to investigate frontal lobe functioning. In the current study we employed a simple response conflict task during fMRI to examine differences in brain activation between patients experiencing their first-episode of psychosis (n = 33) and age- and sex-matched healthy volunteers (n = 33). We further investigated whether baseline brain activation among patients predicted changes in symptom severity and treatment response following 12 weeks of controlled antipsychotic treatment. During the task subjects were instructed to press a response button on the same side or opposite side of a circle that appeared on either side of a central fixation point. Imaging data revealed that for the contrast of opposite-side vs. same-side, patients showed significantly greater activation compared with healthy volunteers in the anterior cingulate cortex and intraparietal sulcus. Among patients, greater baseline anterior cingulate cortex, temporal-parietal junction, and superior temporal cortex activation predicted greater symptom reduction and therapeutic response following treatment. All findings remained significant after covarying for task performance. Intact performance on this relatively parsimonious task was associated with frontal hyperactivity suggesting the need for patients to utilize greater neural resources to achieve task performance comparable to healthy individuals. Moreover, frontal hyperactivity observed using a simple fMRI task may provide a biomarker for predicting treatment response in first-episode psychosis.
Collapse
Affiliation(s)
- Keith M Shafritz
- Department of Psychology, Hofstra University, Hempstead, NY, USA. .,Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research, Manhasset, NY, USA.
| | - Toshikazu Ikuta
- Department of Communication Sciences and Disorders, School of Applied Sciences, University of Mississippi, Oxford, MS, USA
| | - Allison Greene
- Department of Psychology, Hofstra University, Hempstead, NY, USA
| | - Delbert G Robinson
- Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research, Manhasset, NY, USA.,Division of Psychiatry Research, Northwell Health System, Zucker Hillside Hospital, Glen Oaks, NY, USA.,Departments of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, NY, USA
| | - Juan Gallego
- Weill Cornell Medical College, New York, NY, USA.,New York-Presbyterian Hospital/Westchester Division, White Plains, NY, USA
| | - Todd Lencz
- Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research, Manhasset, NY, USA.,Division of Psychiatry Research, Northwell Health System, Zucker Hillside Hospital, Glen Oaks, NY, USA.,Departments of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, NY, USA
| | - Pamela DeRosse
- Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research, Manhasset, NY, USA.,Division of Psychiatry Research, Northwell Health System, Zucker Hillside Hospital, Glen Oaks, NY, USA.,Departments of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, NY, USA
| | - Peter B Kingsley
- Department of Radiology, North Shore University Hospital, Manhasset, NY, USA
| | - Philip R Szeszko
- James J. Peters VA Medical Center, Mental Illness Research Education Clinical Center, Bronx, NY, USA.,Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| |
Collapse
|
28
|
Viúdez A, Carmona-Bayonas A, Gallego J, Lacalle A, Hernández R, Cano JM, Macías I, Custodio A, Martínez de Castro E, Sánchez A, Iglesia L, Reguera P, Visa L, Azkarate A, Sánchez-Cánovas M, Mangas M, Limón ML, Martínez-Torrón A, Asensio E, Ramchandani A, Martín-Carnicero A, Hurtado A, Cerdà P, Garrido M, Sánchez-Bayonas R, Serrano R, Jiménez-Fonseca P. Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry. Clin Transl Oncol 2019; 22:734-750. [PMID: 31385226 DOI: 10.1007/s12094-019-02183-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2019] [Accepted: 07/08/2019] [Indexed: 12/13/2022]
Abstract
BACKGROUND The optimal duration of first-line chemotherapy for patients with advanced gastric cancer is unknown. Diverse clinical trials have proposed different strategies including limited treatment, maintenance of some drugs, or treatment until progression. METHOD The sample comprises patients from the AGAMENON multicenter registry without progression after second evaluation of response. The objective was to explore the optimal duration of first-line chemotherapy. A frailty multi-state model was conducted. RESULTS 415 patients were divided into three strata: discontinuation of platinum and maintenance with fluoropyrimidine until progression (30%, n = 123), complete treatment withdrawal prior to progression (52%, n = 216), and full treatment until progression (18%, n = 76). The hazard of tumor progression decreased by 19% per month with the full treatment regimen. However, we found no evidence that fluoropyrimidine maintenance (hazard ratio [HR] 1.07, confidence interval [CI] 95%, 0.69-1.65) worsened progression-free survival (PFS) with respect to treatment until progression. Predictive factors for PFS were ECOG performance status, ≥ 3 metastatic sites, prior tumor response, and bone metastases. Toxicity grade 3/4 was more common in those who continued the full treatment until progression vs fluoropyrimidine maintenance (16% vs 6%). CONCLUSION The longer duration of the full initial regimen exerted a protective effect on the patients of this registry. Platinum discontinuation followed by fluoropyrimidine maintenance yields comparable efficacy to treatment up to PD, with a lower rate of serious adverse events.
Collapse
Affiliation(s)
- A Viúdez
- Medical Oncology Department, Complejo Hospitalario de Navarra (CHN), OncobionaTras Unit, Navarrabiomed, Navarrabiomed Biomedical Center, IdiSNA, Irunlarrea 3, 31008, Pamplona, Navarra, Spain.
| | - A Carmona-Bayonas
- Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, University of Murcia, IMIB, Murcia, Spain
| | - J Gallego
- Medical Oncology Department, Hospital Universitario de Elche, Elche, Spain
| | - A Lacalle
- Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - R Hernández
- Medical Oncology Department, Hospital Universitario de Canarias, Tenerife, Spain
| | - J M Cano
- Medical Oncology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
| | - I Macías
- Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain
| | - A Custodio
- Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain
| | - E Martínez de Castro
- Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - A Sánchez
- Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain
| | - L Iglesia
- Medical Oncology Department, Complejo Hospitalario de Orense, Orense, Spain
| | - P Reguera
- Medical Oncology Department, Hospital Universitario Ramón Y Cajal, Madrid, Spain
| | - L Visa
- Medical Oncology Department, Hospital Universitario El Mar, Barcelona, Spain
| | - A Azkarate
- Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain
| | - M Sánchez-Cánovas
- Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain
| | - M Mangas
- Medical Oncology Department, Hospital Galdakao-Usansolo, Galdakao-Usansolo, Spain
| | - M L Limón
- Medical Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - A Martínez-Torrón
- Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - E Asensio
- Medical Oncology Department, Hospital Universitario de Elche, Elche, Spain
| | - A Ramchandani
- Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain
| | - A Martín-Carnicero
- Medical Oncology Department, Complejo Hospitalario San Millán, Logroño, Spain
| | - A Hurtado
- Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - P Cerdà
- Medical Oncology Department, Centro Médico Tecknon, Barcelona, Spain
| | - M Garrido
- Medical Oncology Department, Pontificia Universidad Católica de Chile, Santiago de Chile, Chile
| | - R Sánchez-Bayonas
- Medical Oncology Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - R Serrano
- Medical Oncology Department, Hospital Universitario Reina Sofía, Córdoba, Spain
| | - P Jiménez-Fonseca
- Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
| | | |
Collapse
|
29
|
Aparicio J, Virgili A, Capdevila J, Muñoz Boza F, Álvarez R, Bosch C, Cámara J, Fernandez-Martos C, Fernandez-Plana J, Gallego J, Gallego R, Hernández-Yagüe X, Macías Declara I, Rodríguez-Salas N, Vera R, Taberner M, Maurel J. Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Carrato A, Benavides M, Massutí B, Ferreiro-Monteagudo R, García Alfonso P, Falcó E, Reboredo M, Cano T, Gallego J, Viéitez JM, Layos L, Salud A, Polo E, Dotor E, Durán-Ogalla G, Rodriguez-Garrote M, Calvo A, Grande E, Aranda E. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). BMC Cancer 2019; 19:533. [PMID: 31159765 PMCID: PMC6547483 DOI: 10.1186/s12885-019-5753-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2018] [Accepted: 05/27/2019] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Treatment of frail patients with advanced colorectal cancer (CRC) is controversial. This pilot phase II trial aimed to assess the efficacy and safety of regorafenib when administered in first-line to frail patients with advanced CRC. METHODS Frail patients without prior advanced colorectal cancer treatment were included in the study. Definition of frailty was defined per protocol based on dependency criteria, presence of chronic comorbid pathologies and/or geriatric features. MAIN OBJECTIVE to assess progression-free survival (PFS) rate at 6 months. Treatment consisted of 28-day cycles of orally administered regorafenib 160 mg/day (3 weeks followed by 1 week rest). RESULTS Forty-seven patients were included in the study. Median age was 81 years (range 63-89). Frailty criteria: dependency was observed in 26 patients (55%), comorbidities in 27 (57%) and geriatric features in 18 (38%). PFS rate at 6 months was 45% (95% confidence interval [CI] 30-60]. Median PFS was 5.6 months (95%CI 2.7-8.4). Median overall survival (OS) was 16 months (95%CI 7.8-24). Complete response, partial response and stable disease were observed in one, two and 21 patients respectively (objective response rate 6.4%; disease control rate 51%). Thirty-nine patients (83%) experienced grade 3-4 adverse events (AEs). The most common grade 3-4 AEs were hypertension (15 patients; 32%), asthenia (14; 30%), hypophosphatemia (6; 13%); diarrhea (4; 8%), hand-foot-skin reaction (4; 8%). There were two toxic deaths (4.2%) (grade 5 rectal bleeding and death not further specified). Dose reduction was required in 26 patients (55%) and dose-delays in 13 patients (28%). CONCLUSIONS The study did not meet the pre-specified boundary of 55% PFS rate at 6 months. Toxicity observed (83% patients experienced grade 3 and 4 AEs) preclude its current use in clinical practice on this setting. Disease control rate and overall survival results are interesting and might warrant further investigation to identify those who benefit from this approach. TRIAL REGISTRATION This trial was prospectively registered at EudraCT ( 2013-000236-94 ). Date of trial registration: April 9th, 2013.
Collapse
Affiliation(s)
- A. Carrato
- Medical Oncology Department, Hospital Universitario Ramón y Cajal, IRYCIS, CIBERONC, Alcala University, Ctra. De Colmenar Viejo, km 9,100, 28034 Madrid, Spain
| | - M. Benavides
- Hospital Regional Universitario Virgen de la Victoria, Málaga, Spain
| | - B. Massutí
- Hospital General Universitario de Alicante, Alicante, Spain
| | - R. Ferreiro-Monteagudo
- Medical Oncology Department, Hospital Universitario Ramón y Cajal, IRYCIS, CIBERONC, Alcala University, Ctra. De Colmenar Viejo, km 9,100, 28034 Madrid, Spain
| | | | - E. Falcó
- Hospital Son Llatzer, Mallorca, Spain
| | - M. Reboredo
- Complejo Hospitalario Universitario A Coruña, La Coruña, Spain
| | - T. Cano
- Hospital Universitario Reina Sofia, IMIBIC, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Córdoba, Spain
| | - J. Gallego
- Hospital General Universitario de Elche, Alicante, Spain
| | - J. M. Viéitez
- Hospital Universitario Central de Asturias, Oviedo, Spain
| | - L. Layos
- Hospital Germans Trias i Pujol, ICO, Badalona, Spain
| | - A. Salud
- Hospital de Lleida Arnau de Vilanova, Lérida, Spain
| | - E. Polo
- Hospital Miguel Servet, Zaragoza, Spain
| | - E. Dotor
- Corporació Sanitària Parc Taulí, Barcelona, Spain
| | - G. Durán-Ogalla
- Hospital Regional Universitario Virgen de la Victoria, Málaga, Spain
| | - M. Rodriguez-Garrote
- Medical Oncology Department, Hospital Universitario Ramón y Cajal, IRYCIS, CIBERONC, Alcala University, Ctra. De Colmenar Viejo, km 9,100, 28034 Madrid, Spain
| | - A. Calvo
- Hospital Gregorio Marañón, Madrid, Spain
| | - E. Grande
- Medical Oncology Department, Hospital Universitario Ramón y Cajal, IRYCIS, CIBERONC, Alcala University, Ctra. De Colmenar Viejo, km 9,100, 28034 Madrid, Spain
| | - E. Aranda
- Hospital Universitario Reina Sofia, IMIBIC, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Córdoba, Spain
| |
Collapse
|
31
|
Huguet JM, Ferrer-Barceló L, Suárez P, Albert C, Gonzalez L, Castillo G, Boix C, García L, Gallego J, Sempere J. Endoscopic progression of ulcerative proctitis to proximal disease. Can we identify predictors of progression? Scand J Gastroenterol 2019; 53:1286-1290. [PMID: 30351984 DOI: 10.1080/00365521.2018.1524026] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
INTRODUCTION Ulcerative proctitis is a type of ulcerative colitis circumscribed to the rectum. Proximal progression rates of the disease have been reported as between 27% and 54%. Several predictive factors have been identified for its progression; however, none has been established as definitive. MATERIAL AND METHODS Retrospective study of patients diagnosed with ulcerative proctitis with at least 12 months of follow-up. Patients diagnosed between January 1992 and March 2017. Variables were collected at the time of diagnosis and during the first year of follow-up. The extent of the progression was evaluated endoscopically during follow-up. The endoscopic progression rate was determined and possible risk factors related to this progression were evaluated. RESULTS The analysis involved 137 patients. In 77 of the patients, we performed a second colonoscopy during follow-up to evaluate endoscopic progression. The average time before the second colonoscopy performed was 5 years (SD 3.9). Of the 77 patients, 32 (41.6%) presented proximal progression to the rectosigmoid junction. Logistic regression analysis showed a statistically significant association for progression in patients who had suffered one or more flares in the first year following diagnosis. Significant progression was also observed in those with the longest time of progression at the final colonoscopy. CONCLUSIONS Ulcerative proctitis is not a stable disease over time. In addition, during the first year of the disease progression, it is possible to predict in which patients the disease will progress to more extensive forms.
Collapse
Affiliation(s)
- Jose María Huguet
- a Digestive Disease Department , General University Hospital of Valencia , Valencia , Spain
| | - Luis Ferrer-Barceló
- a Digestive Disease Department , General University Hospital of Valencia , Valencia , Spain
| | - Patrícia Suárez
- a Digestive Disease Department , General University Hospital of Valencia , Valencia , Spain
| | - Cecilia Albert
- a Digestive Disease Department , General University Hospital of Valencia , Valencia , Spain
| | - Lara Gonzalez
- a Digestive Disease Department , General University Hospital of Valencia , Valencia , Spain
| | - Genesis Castillo
- a Digestive Disease Department , General University Hospital of Valencia , Valencia , Spain
| | - Carlos Boix
- a Digestive Disease Department , General University Hospital of Valencia , Valencia , Spain
| | - Laura García
- a Digestive Disease Department , General University Hospital of Valencia , Valencia , Spain
| | - Juan Gallego
- a Digestive Disease Department , General University Hospital of Valencia , Valencia , Spain
| | - Javier Sempere
- a Digestive Disease Department , General University Hospital of Valencia , Valencia , Spain
| |
Collapse
|
32
|
Vidal J, Bellosillo B, Santos Vivas C, García-Alfonso P, Carrato A, Cano MT, García-Carbonero R, Élez E, Losa F, Massutí B, Valladares-Ayerbes M, Viéitez JM, Manzano JL, Azuara D, Gallego J, Pairet S, Capellá G, Salazar R, Tabernero J, Aranda E, Montagut C. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy. Ann Oncol 2019; 30:439-446. [PMID: 30689692 DOI: 10.1093/annonc/mdz005] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND Extended RAS analysis is mandatory in metastatic colorectal cancer (mCRC) patients. The optimal threshold of RAS mutated subclones to identify patients most likely to benefit from antiepidermal growth factor receptor (EGFR) therapy is controversial. Our aim was to assess the clinical impact of detecting mutations in RAS, BRAF, PIK3CA and EGFRS492R in basal tissue tumour samples by using a highly sensitive next-generation sequencing (NGS) technology in mCRC patients treated with chemotherapy plus anti-EGFR or anti-vascular endothelial growth factor. PATIENTS AND METHODS Five hundred and eighty-one tumour samples from untreated mCRC patients from 7 clinical studies were collected. Mutational analysis was carried out by standard-of-care (therascreen pyro) with a sensitivity detection of 5% mutant allele fraction (MAF), and compared with NGS technology using 454GS Junior platform (Roche Applied Science, Germany) with a sensitivity of 1%. Molecular results were correlated with clinical outcomes. RESULTS After quality assessment, 380 samples were evaluable for molecular analysis. Standard-of-care mutational analysis detected RAS, BRAFV600E or PIK3CA mutations in 56.05% of samples compared with 69.21% by NGS (P = 0.00018). NGS identified coexistence of multiple low-frequency mutant alleles in 96 of the 263 mutated cases (36.5%; range 2-7). Response rate (RR), progression-free survival (PFS) and overall survival (OS) were increasingly improved in patients with RAS wild-type, RAS/BRAF wild-type or quadruple (KRAS/NRAS/BRAF/PIK3CA) wild-type tumours treated with anti-EGFR, assessed by standard-of-care. No additional benefit in RR, PFS or OS was observed by increasing the detection threshold to 1% by NGS. An inverse correlation between the MAF of the most prevalent mutation detected by NGS and anti-EGFR response was observed (P = 0.039). EGFRS492Rmutation was not detected in untreated samples. CONCLUSIONS No improvement in the selection of patients for anti-EGFR therapy was obtained by adjusting the mutation detection threshold in tissue samples from 5% to 1% MAF. Response to anti-EGFR was significantly better in patients with quadruple wild-type tumours.
Collapse
Affiliation(s)
- J Vidal
- Medical Oncology Department, Hospital del Mar-IMIM, CIBERONC Instituto de Salud Carlos III, Barcelona
| | - B Bellosillo
- Pathology Department, Hospital del Mar, Barcelona
| | - C Santos Vivas
- Translational Research Laboratory, Medical Oncology Department, Catalan Institute of Oncology (ICO), ICO-Bellvitge Biomedical Research Institute (IDIBELL)-CIBERONC Instituto de Salud Carlos III, L'Hospitalet de Llobregat, Barcelona
| | | | - A Carrato
- Medical Oncology Department, Hospital Ramón y Cajal, IRYCIS, CIBERONC Instituto de Salud Carlos III, Alcala University, Madrid
| | - M T Cano
- Medical Oncology Department, IMIBIC, Reina Sofía Hospital, University of Cordoba, CIBERONC Instituto de Salud Carlos III
| | - R García-Carbonero
- Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre, (imas12), UCM, CNIO, CIBERONC Instituto de Salud Carlos III, Madrid
| | - E Élez
- Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), CIBERONC Instituto de Salud Carlos III, Universitat Autònoma de Barcelona, Barcelona
| | - F Losa
- Medical Oncology Department, Hospital Sant Joan Despí - Moisés Broggi, Barcelona
| | - B Massutí
- Medical Oncology Department, Hospital General Universitario, Alicante
| | - M Valladares-Ayerbes
- Medical Oncology Department, Complejo Hospitalario Universitario de A Coruña, A Coruña
| | - J M Viéitez
- Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo
| | - J L Manzano
- Medical Oncology Department, ICO, Badalona, Barcelona
| | - D Azuara
- Translational Research Laboratory, Medical Oncology Department, Catalan Institute of Oncology (ICO), ICO-Bellvitge Biomedical Research Institute (IDIBELL)-CIBERONC Instituto de Salud Carlos III, L'Hospitalet de Llobregat, Barcelona
| | - J Gallego
- Medical Oncology Department, Hospital General Universitario de Elche, Alicante
| | - S Pairet
- Pathology Department, Hospital del Mar, Barcelona
| | - G Capellá
- Faculty of Medicine, Department of Clinical Sciences, Translational Research Laboratory, ICO-IDIBELL, L'Hospitalet de Llobregat, University of Barcelona, CIBERONC Instituto de Salud Carlos III, Barcelona, Spain
| | - R Salazar
- Translational Research Laboratory, Medical Oncology Department, Catalan Institute of Oncology (ICO), ICO-Bellvitge Biomedical Research Institute (IDIBELL)-CIBERONC Instituto de Salud Carlos III, L'Hospitalet de Llobregat, Barcelona
| | - J Tabernero
- Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), CIBERONC Instituto de Salud Carlos III, Universitat Autònoma de Barcelona, Barcelona
| | - E Aranda
- Medical Oncology Department, IMIBIC, Reina Sofía Hospital, University of Cordoba, CIBERONC Instituto de Salud Carlos III
| | - C Montagut
- Medical Oncology Department, Hospital del Mar-IMIM, CIBERONC Instituto de Salud Carlos III, Barcelona.
| |
Collapse
|
33
|
Grau Amorós J, Formiga F, Aramburu Bodas O, Armengou Arxe A, Conde Martel A, Quesada Simón M, Oropesa Juanes R, Satué Bartolomé J, Dávila Ramos M, Montero Pérez-Barquero M, Anarte L, Aramburu O, Arévalo-Lorido J, Armengou A, Brase A, Carrascosa S, Carrera M, Casado J, Cerqueiro J, Conde A, Dávila M, Díez-Manglano J, Epelde F, Formiga F, Franco J, Gallego J, García-Escrivá D, González-Franco A, Grau J, Guisado M, Herrero A, Llacer P, López-Castellanos G, Manzano L, Martínez-Zapico A, Montero-Pérez-Barquero M, Muela A, Oropesa R, Pérez-Bocanegra C, Pérez-Calvo J, Pérez-Silvestre J, Quesada M, Quirós R, Rodríguez-Ávila E, Ruiz-Laiglesia F, Ruiz-Ortega R, Salamanca P, Sánchez-Marteles M, Satué J, Serrado A, Suárez I, Trullàs J. Hemoconcentración como predictor de supervivencia al año de ingreso por insuficiencia cardiaca aguda en el registro RICA. Rev Clin Esp 2019; 219:1-9. [DOI: 10.1016/j.rce.2018.07.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Revised: 07/05/2018] [Accepted: 07/06/2018] [Indexed: 02/04/2023]
|
34
|
Grau Amorós J, Formiga F, Aramburu Bodas O, Armengou Arxe A, Conde Martel A, Quesada Simón M, Oropesa Juanes R, Satué Bartolomé J, Dávila Ramos M, Montero Pérez-Barquero M, Anarte L, Aramburu O, Arévalo-Lorido J, Armengou A, Brase A, Carrascosa S, Carrera M, Casado J, Cerqueiro J, Conde A, Dávila M, Díez-Manglano J, Epelde F, Formiga F, Franco J, Gallego J, García-Escrivá D, González-Franco A, Grau J, Guisado M, Herrero A, Llacer P, López-Castellanos G, Manzano L, Martínez-Zapico A, Montero-Pérez-Barquero M, Muela A, Oropesa R, Pérez-Bocanegra C, Pérez-Calvo J, Pérez-Silvestre J, Quesada M, Quirós R, Rodríguez-Ávila E, Ruiz-Laiglesia F, Ruiz-Ortega R, Salamanca P, Sánchez-Marteles M, Satué J, Serrado A, Suárez I, Trullàs J. Hemoconcentration as a prognostic factor after hospital discharge in acute heart failure in the RICA registry. Rev Clin Esp 2019. [DOI: 10.1016/j.rceng.2018.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
35
|
Zhang JP, Robinson D, Yu J, Gallego J, Wolfgang Fleischhacker W, Kahn RS, Crespo-Facorro B, Vazquez-Bourgon J, Kane JM, Malhotra AK, Lencz T. Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis. Am J Psychiatry 2019; 176:21-28. [PMID: 30392411 PMCID: PMC6461047 DOI: 10.1176/appi.ajp.2018.17121363] [Citation(s) in RCA: 102] [Impact Index Per Article: 20.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE Pharmacogenomic studies of antipsychotics have typically examined effects of individual polymorphisms. By contrast, polygenic risk scores (PRSs) derived from genome-wide association studies (GWAS) can quantify the influence of thousands of common alleles of small effect in a single measure. The authors examined whether PRSs for schizophrenia were predictive of antipsychotic efficacy in four independent cohorts of patients with first-episode psychosis (total N=510). METHOD All study subjects received initial treatment with antipsychotic medication for first-episode psychosis, and all were genotyped on standard single-nucleotide polymorphism (SNP) arrays imputed to the 1000 Genomes Project reference panel. PRS was computed based on the results of the large-scale schizophrenia GWAS reported by the Psychiatric Genomics Consortium. Symptoms were measured by using total symptom rating scales at baseline and at week 12 or at the last follow-up visit before dropout. RESULTS In the discovery cohort, higher PRS significantly predicted higher symptom scores at the 12-week follow-up (controlling for baseline symptoms, sex, age, and ethnicity). The PRS threshold set at a p value <0.01 gave the strongest result in the discovery cohort and was used to replicate the findings in the other three cohorts. Higher PRS significantly predicted greater posttreatment symptoms in the combined replication analysis and was individually significant in two of the three replication cohorts. Across the four cohorts, PRS was significantly predictive of adjusted 12-week symptom scores (pooled partial r=0.18; 3.24% of variance explained). Patients with low PRS were more likely to be treatment responders than patients with high PRS (odds ratio=1.91 in the two Caucasian samples). CONCLUSIONS Patients with higher PRS for schizophrenia tended to have less improvement with antipsychotic drug treatment. PRS burden may have potential utility as a prognostic biomarker.
Collapse
Affiliation(s)
- Jian-Ping Zhang
- Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Departments of Psychiatry and Molecular Medicine, Hempstead, NY, USA,The Zucker Hillside Hospital, Division of Psychiatry Research, Northwell Health, Glen Oaks, NY, USA,The Feinstein Institute for Medical Research, Center for Psychiatric Neuroscience, Manhasset, NY, USA
| | - Delbert Robinson
- Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Departments of Psychiatry and Molecular Medicine, Hempstead, NY, USA,The Zucker Hillside Hospital, Division of Psychiatry Research, Northwell Health, Glen Oaks, NY, USA,The Feinstein Institute for Medical Research, Center for Psychiatric Neuroscience, Manhasset, NY, USA
| | - Jin Yu
- The Zucker Hillside Hospital, Division of Psychiatry Research, Northwell Health, Glen Oaks, NY, USA
| | - Juan Gallego
- Weill Cornell Medical College, NewYork-Presbyterian/Westchester Division, White Plains, NY, USA
| | | | - Rene S. Kahn
- Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Benedicto Crespo-Facorro
- Department of Medicine and Psychiatry, University of Cantabria, CIBERSAM, IDIVAL, University Hospital Marqués de Valdecilla, Santander, Spain
| | - Javier Vazquez-Bourgon
- Department of Medicine and Psychiatry, University of Cantabria, CIBERSAM, IDIVAL, University Hospital Marqués de Valdecilla, Santander, Spain
| | - John M. Kane
- Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Departments of Psychiatry and Molecular Medicine, Hempstead, NY, USA,The Zucker Hillside Hospital, Division of Psychiatry Research, Northwell Health, Glen Oaks, NY, USA,The Feinstein Institute for Medical Research, Center for Psychiatric Neuroscience, Manhasset, NY, USA
| | - Anil K. Malhotra
- Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Departments of Psychiatry and Molecular Medicine, Hempstead, NY, USA,The Zucker Hillside Hospital, Division of Psychiatry Research, Northwell Health, Glen Oaks, NY, USA,The Feinstein Institute for Medical Research, Center for Psychiatric Neuroscience, Manhasset, NY, USA
| | - Todd Lencz
- Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Departments of Psychiatry and Molecular Medicine, Hempstead, NY, USA,The Zucker Hillside Hospital, Division of Psychiatry Research, Northwell Health, Glen Oaks, NY, USA,The Feinstein Institute for Medical Research, Center for Psychiatric Neuroscience, Manhasset, NY, USA
| |
Collapse
|
36
|
Gómez-España MA, Gallego J, González-Flores E, Maurel J, Páez D, Sastre J, Aparicio J, Benavides M, Feliu J, Vera R. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). Clin Transl Oncol 2018; 21:46-54. [PMID: 30565083 PMCID: PMC6339676 DOI: 10.1007/s12094-018-02002-w] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2018] [Accepted: 11/28/2018] [Indexed: 12/22/2022]
Abstract
Colorectal cancer (CRC) is the second cause of cancer death in Spain, the objective of this guide published by the Spanish Society of Medical Oncology is to develop a consensus for the diagnosis and management of metastatic disease. The optimal treatment strategy for patients with metastatic CRC should be discussed in a multidisciplinary expert team to select the most appropriate treatment, and integrate systemic treatment and other options such as surgery and ablative techniques depending on the characteristics of the tumour, the patient and the location of the disease and metastases.
Collapse
Affiliation(s)
- M A Gómez-España
- Servicio de Oncología Médica, H. Universitario Reina Sofía, IMIBIC, CIBERONC, Av. Menéndez Pidal, s/n, 14004, Córdoba, Spain.
| | - J Gallego
- Servicio de Oncología Médica, Hospital General Universitario, Elche, Spain
| | - E González-Flores
- Servicio de Oncología Médica, H. U. Virgen de las Nieves, Granada, Spain
| | - J Maurel
- Servicio de Oncología Médica, Hospital Clinic, Barcelona, Spain
| | - D Páez
- Servicio de Oncología Médica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - J Sastre
- Servicio de Oncología Médica, Hospital Clínico San Carlos, IdISSC, CIBERONC, Madrid, Spain
| | - J Aparicio
- Servicio de Oncología Médica, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - M Benavides
- Servicio de Oncología Médica, H.U. Regional y Virgen de la Victoria, Málaga, Spain
| | - J Feliu
- Servicio de Oncología Médica, H. U. La Paz, UAM, CIBERONC, Madrid, Spain
| | - R Vera
- Servicio de Oncología Médica, Complejo Hospitalario de Navarra, IdiSNA, Pamplona, Spain
| |
Collapse
|
37
|
Gallego J, Alt W, Macha T, Martinez-Dorantes M, Pandey D, Meschede D. Strong Purcell Effect on a Neutral Atom Trapped in an Open Fiber Cavity. Phys Rev Lett 2018; 121:173603. [PMID: 30411925 DOI: 10.1103/physrevlett.121.173603] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Indexed: 06/08/2023]
Abstract
We observe a sixfold Purcell broadening of the D_{2} line of an optically trapped ^{87}Rb atom strongly coupled to a fiber cavity. Under external illumination by a near-resonant laser, up to 90% of the atom's fluorescence is emitted into the resonant cavity mode. The sub-Poissonian statistics of the cavity output and the Purcell enhancement of the atomic decay rate are confirmed by the observation of a strongly narrowed antibunching dip in the photon autocorrelation function. The photon leakage through the higher-transmission mirror of the single-sided resonator is the dominant contribution to the field decay (κ≈2π×50 MHz), thus offering a high-bandwidth, fiber-coupled channel for photonic interfaces such as quantum memories and single-photon sources.
Collapse
Affiliation(s)
- J Gallego
- Institut für Angewandte Physik der Universität Bonn, Wegelerstrasse 8, D-53115 Bonn, Germany
| | - W Alt
- Institut für Angewandte Physik der Universität Bonn, Wegelerstrasse 8, D-53115 Bonn, Germany
| | - T Macha
- Institut für Angewandte Physik der Universität Bonn, Wegelerstrasse 8, D-53115 Bonn, Germany
| | - M Martinez-Dorantes
- Institut für Angewandte Physik der Universität Bonn, Wegelerstrasse 8, D-53115 Bonn, Germany
| | - D Pandey
- Institut für Angewandte Physik der Universität Bonn, Wegelerstrasse 8, D-53115 Bonn, Germany
| | - D Meschede
- Institut für Angewandte Physik der Universität Bonn, Wegelerstrasse 8, D-53115 Bonn, Germany
| |
Collapse
|
38
|
Vidal J, Dalmeses A, Vivas CS, Garcia-Carbonero R, García-Alfonso P, Carrato A, Elez E, Ortiz M, Losa F, Massutí B, Valladares-Ayerbes M, Manzano J, de Prado JV, Gallego J, Grávalos C, Varela M, Azuara D, Tabernero J, Salazar R, Aranda E, Bellosillo B, Montagut C. Ultra-selection of metastatic colorectal cancer patients using next generation sequencing platform to improve clinical efficacy of anti-EGFR therapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy149.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Pericay C, Gallego J, Montes AF, Oliveres H, Asensio-Martínez H, Garcia-Gómez J, Fernandez-Plana J, Marín-Alcalá M, Ballester-Espinosa M, Salgado M, Declara IM, Gómez-González L, Iglesias-Rey L, Cirera L. Real world data in colorectal cancer: A retrospective analysis of overall survival in metastatic colorectal cancer patients between 2011-2015 treated in Spain, preliminary results (RWD-ACROSS study). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.276] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Abstract
Background Genetic variants in miRNA genes and abnormalities in the concentration of microRNAs (miRNAs) in tissues and biological fluids have recently been associated with a diagnosis of schizophrenia. Most of these studies used post-mortem brain tissue or whole blood as the source of RNA. However, examination of microRNAs in cerebrospinal fluid (CSF) might provide an in vivo biomarker, more accurately reflecting expression level changes in the brain. To date, there are no studies that have investigated miRNA expression in CSF in patients with schizophrenia using small RNA-seq. In the past, our group had the opportunity of investigating the correlation between miRNA profiles in CSF and blood measured using microarray technology. Therefore, to expand our findings and use current cutting-edge technology, we measured miRNA profiles in CSF and plasma using small RNA-seq in a sample of patients with schizophrenia-spectrum disorder (SSD) diagnosis and healthy volunteers. Methods Twenty-two SSD patients and 17 healthy volunteers underwent a lumbar puncture and a blood draw. 15–25 cc of CSF and 5–10 cc of peripheral blood were obtained from each subject. CSF and peripheral blood samples were centrifuged. CSF and plasma samples were aliquoted into 1 mL cryovials, and stored at -80C degrees. Vesicular RNA was extracted from 1 mL of CSF and plasma samples following the protocol from the Qiagen exoRNA easy kit. The BioScientific NextFlex RNA sequencing kit was used for library construction. Sequencing was done on HiSeq2500. Samples that had at least 50,000 reads going to mature miRNA sequences were included in the analysis. Differential expression analyses were conducted in R using the DESeq2 package in Bioconductor. Results In the overall sample cohort, most subjects were male (66.7%), not Hispanic (81.0%) and black (48.7%). Mean age was 36.8 years (SD=12.3), There were no differences in age, sex, ethnicity or race between the patient and healthy control groups. In the patient group, 16 (72.7%) had schizophrenia, 5 (22.7%) had schizoaffective disorder and 1 (4.5%) had psychosis not otherwise specified. Differential expression (DE) analyses were conducted for 144 miRNAs in CSF and 354 miRNAs in plasma. After adjusting for multiple comparisons, DE analysis between patients and controls in CSF showed statistically significant higher levels in patients of miR-769-5p, miR-99b-3p, miR-107, miR-451a and miR-708-5. Similar analysis in plasma showed statistically significant higher levels in patients for miR-375, miR-204-5p, miR-942-5p, miR-6734-5p, miR-423-5p and miR-144-5p. Principal component analysis showed a clear separation between CSF and peripheral blood samples. Out of 443 miRNAs used to examine the relationship between CSF and plasma, 205 (46.3%) were detected in both plasma and CSF samples, 88 (19.9%) were detected only in CSF samples while 150 (33.9%) were detected only in plasma samples. Discussion Five miRNAs were upregulated in CSF samples and six were upregulated in plasma samples of SSD patients compared to healthy volunteers. There was no overlap in the statistically significant upregulated miRNAs between CSF and plasma samples. Therefore, miRNA profiles in CSF and plasma have important quantitative and qualitative differences that may make them excellent, but different, candidate biofluids for biomarker discovery.
Collapse
Affiliation(s)
| | - Eric Alsop
- The Translational Genomics Research Institute
| | - Todd Lencz
- Zucker Hillside Hospital, Feinstein Institute for Medical Research
| | | | - Anil Malhotra
- Zucker Hillside Hospital, Feinstein Institute for Medical Research
| |
Collapse
|
41
|
Abad A, Martínez-Balibrea E, Viéitez J, Alonso-Orduña V, García Alfonso P, Manzano J, Massutí B, Benavides M, Carrato A, Zanui M, Gallego J, Grávalos C, Conde V, Provencio M, Valladares-Ayerbes M, Salazar R, Sastre J, Montagut C, Rivera F, Aranda E. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. Ann Oncol 2018; 29:439-444. [DOI: 10.1093/annonc/mdx737] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
42
|
Carmona-Bayonas A, Jiménez-Fonseca P, Custodio A, Sánchez Cánovas M, Hernández R, Pericay C, Echavarria I, Lacalle A, Visa L, Rodríguez Palomo A, Mangas M, Cano JM, Buxo E, Álvarez-Manceñido F, García T, Lorenzo JE, Ferrer-Cardona M, Viudez A, Azkarate A, Ramchandani A, Arias D, Longo F, López C, Sánchez Bayona R, Limón ML, Díaz-Serrano A, Fernández Montes A, Sala P, Cerdá P, Rivera F, Gallego J. Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry. Gastric Cancer 2018; 21:96-105. [PMID: 28393278 DOI: 10.1007/s10120-017-0718-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2017] [Accepted: 04/03/2017] [Indexed: 02/07/2023]
Abstract
BACKGROUND Although anthracycline-based triplets are one of the most widely used schedules to treat advanced gastric cancer (AGC), the benefit of including epirubicin in these therapeutic combinations remains unknown. This study aims to evaluate both the efficacy and tolerance of triplets with epirubicin vs. doublets with platinum-fluoropyrimidine in a national AGC registry. METHODS Patients with AGC treated with polychemotherapy without trastuzumab at 28 hospitals in Spain between 2008 and 2016 were included. The effect of anthracycline-based triplets against doublets was evaluated by propensity score matching (PSM) and Cox proportional hazards (PH) regression. RESULT A total of 1002 patients were included (doublets, n = 653; anthracycline-based triplets, n = 349). The multivariable Cox PH regression failed to detect significantly increased OS in favor of triplets with anthracyclines: HR 0.90 (95% CI, 0.78-1.05), p = 0.20035. After PSM, the sample contained 325 pairs with similar baseline characteristics. This method was also unable to reveal an increase in OS: 10.5 (95% CI, 9.7-12.3) vs. 9.9 (95% CI, 9.2-11.4) months, HR 0.91 (CI 95%, 0.76-1.083), and (log-rank test, p = 0.226). Response rates (42.1 vs. 33.1%, p = 0.12) and PFS (HR 0.95, CI 95%, 0.80-1.13, log-rank test, p = 0.873) were not significantly higher with epirubicin-based regimens. The triplets were associated with greater grade 3-4 hematological toxicity, and increased hospitalization due to toxicity by 68%. The addition of epirubicin is viable, but 23.7% discontinued treatment because of adverse effects or patient decision. CONCLUSION Anthracyclines added to platinum-fluoropyrimidine doublets did not improve the response rate or survival outcomes in patients with AGC but entailed greater toxicity.
Collapse
Affiliation(s)
- A Carmona-Bayonas
- Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, IMIB, Avenida Marqués de los Vélez, 30008, Murcia, Spain.
| | - P Jiménez-Fonseca
- Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - A Custodio
- Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain
| | - M Sánchez Cánovas
- Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, IMIB, Avenida Marqués de los Vélez, 30008, Murcia, Spain
| | - R Hernández
- Medical Oncology Department, Hospital Universitario de Canarias, Tenerife, Spain
| | - C Pericay
- Medical Oncology Department, Corporació Sanitària Parc Taulí , Sabadell, Spain
| | - I Echavarria
- Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain
| | - A Lacalle
- Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - L Visa
- Medical Oncology Department, Hospital Universitario Del Mar, Barcelona, Spain
| | - A Rodríguez Palomo
- Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - M Mangas
- Medical Oncology Department, Hospital Galdakao-Usansolo, Galdakao-Usansolo, Spain
| | - J M Cano
- Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain
| | - E Buxo
- Medical Oncology Department, Hospital Universitario Clinic, Barcelona, Spain
| | - F Álvarez-Manceñido
- Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - T García
- Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, IMIB, Avenida Marqués de los Vélez, 30008, Murcia, Spain
| | - J E Lorenzo
- Medical Oncology Department, Hospital Universitario de Canarias, Tenerife, Spain
| | - M Ferrer-Cardona
- Medical Oncology Department, Corporació Sanitària Parc Taulí , Sabadell, Spain
| | - A Viudez
- Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - A Azkarate
- Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain
| | - A Ramchandani
- Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain
| | - D Arias
- Medical Oncology Department, Complejo Hospitalario de Orense, Orense, Spain
| | - F Longo
- Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - C López
- Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - R Sánchez Bayona
- Medical Oncology Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - M L Limón
- Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain
| | - A Díaz-Serrano
- Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain
| | - A Fernández Montes
- Medical Oncology Department, Complejo Hospitalario de Orense, Orense, Spain
| | - P Sala
- Medical Oncology Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - P Cerdá
- Medical Oncology Department, Clínica Tecknon de Barcelona, Barcelona, Spain
| | - F Rivera
- Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - J Gallego
- Medical Oncology Department, Hospital General Universitario de Elche, Elche, Spain
| | | |
Collapse
|
43
|
Escribá A, Maluenda MP, Rubio M, Margalet I, Lezana A, Gallego J, Ribera JM, Veiga F. Low Molecular Weight Heparin (Enoxaparin) Versus Oral Anticoagulant Therapy (Acenocoumarol) in the Long-Term Treatment of Deep Venous Thrombosis in the Elderly: a Randomized Trial. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1614067] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryThis study aims to establish the relative effectiveness and safety of low molecular weight heparin in elderly patients with venous thrombosis in order to find an alternative to oral anticoagulant therapy with less bleeding complications in the long-term treatment of deep venous thrombosis (DVT).One hundred consecutive elderly patients (>75 years old) with venographically demonstrated proximal DVT were included in a randomized trial. All patients were treated for ten days with adjusted doses of intravenous heparin. Informed consent was obtained and on the eight day, patients were randomly allocated to receive acenocoumarol (INR 2.0-3.0) or subcutaneous enoxaparin (4000 anti-Xa units once a day) for three months. All patients were followed-up clinically and venographically for a one year period. The results were analyzed with Fisher’s exact test or chi-square test as appropriate.During the treatment and surveillance period, 6 of the 50 patients (12%) who received acenocoumarol and 8 of the 50 patients (16%) who received enoxaparin had new episodes of venous thromboembolism confirmed by objective testing (p = 0.6; 95% CI for the difference: −19.5 to 11.5). Hemorrhagic complications occurred in six of the 50 patients (12%) who received acenocoumarol and in one (2%) of those on enoxaparin (p = 0.1; 95% CI for the difference: -1.8 to 21.8). Vertebral fractures developed in 2 patients (4%) in the enoxaparin group (p = 0.5; 95% CI for the diference: −11.4 to 3.4).These results show that fixed dose enoxaparin seems to be effective and safe in the long-term treatment of proximal DVT in the elderly. In comparison with oral anticoagulants, the findings are inconclusive due to the wide confidence intervals for differences between outcomes, however they suggest that the former may have less bleeding complications with similar efficacy.
Collapse
|
44
|
Gallego J, López C, Pazo-Cid R, López-Ríos F, Carrato A. Biomarkers in pancreatic ductal adenocarcinoma. Clin Transl Oncol 2017; 19:1430-1437. [PMID: 28616721 DOI: 10.1007/s12094-017-1691-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2017] [Accepted: 05/24/2017] [Indexed: 12/18/2022]
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is currently the third most frequent form of malignancy. The role of biomarkers in the diagnostic and therapeutic strategy of cancer is constantly expanding. Translational research is already changing paradigms in tumours encompassing from early diagnosis to precision medicine in advanced disease. Nomenclature for molecular subtypes of tumours is gradually gaining acceptance and there are growing expectations it will further go from the bench to the bedside. However, the clinical relevance of biomarkers in PDAC is still far behind the relevance of biomarkers in other solid tumours. This article is part of a wider project (GALLgo) involving over forty specialists devoted to the multidisciplinary management of PDAC which concluded in recommendations based on scientific evidence. The aim of the present article is to review the diagnostic, prognostic and predictive biomarkers, either in localised or advanced disease, which have been lately subjected to study and analysis and others currently available for PDAC in order to give strength-graded recommendations linked to quality of evidence that can be used as guidelines in routine clinical practice.
Collapse
Affiliation(s)
- J Gallego
- Department of Medical Oncology, University Hospital of Elche, Camí de l'Almazara, 11, Elche, 03203, Alicante, Spain.
| | - C López
- Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - R Pazo-Cid
- Department of Medical Oncology, Hospital Universitario Miguel Servet, Saragossa, Spain
| | - F López-Ríos
- Department of Pathology, Laboratorio de Dianas Terapéuticas, Hospital Universitario HM Sanchinarro, Madrid, Spain
| | - A Carrato
- Department of Medical Oncology, Madrid, Spain
| |
Collapse
|
45
|
Martinez-Dorantes M, Alt W, Gallego J, Ghosh S, Ratschbacher L, Völzke Y, Meschede D. Fast Nondestructive Parallel Readout of Neutral Atom Registers in Optical Potentials. Phys Rev Lett 2017; 119:180503. [PMID: 29219582 DOI: 10.1103/physrevlett.119.180503] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Indexed: 06/07/2023]
Abstract
We demonstrate the parallel and nondestructive readout of the hyperfine state for optically trapped ^{87}Rb atoms. The scheme is based on state-selective fluorescence imaging and achieves detection fidelities >98% within 10 ms, while keeping 99% of the atoms trapped. For the readout of dense arrays of neutral atoms in optical lattices, where the fluorescence images of neighboring atoms overlap, we apply a novel image analysis technique using Bayesian inference to determine the internal state of multiple atoms. Our method is scalable to large neutral atom registers relevant for future quantum information processing tasks requiring fast and nondestructive readout and can also be used for the simultaneous readout of quantum information stored in internal qubit states and in the atoms' positions.
Collapse
Affiliation(s)
- M Martinez-Dorantes
- Institut für Angewandte Physik der Universität Bonn, Wegelerstrasse 8, 53115 Bonn, Germany
| | - W Alt
- Institut für Angewandte Physik der Universität Bonn, Wegelerstrasse 8, 53115 Bonn, Germany
| | - J Gallego
- Institut für Angewandte Physik der Universität Bonn, Wegelerstrasse 8, 53115 Bonn, Germany
| | - S Ghosh
- Institut für Angewandte Physik der Universität Bonn, Wegelerstrasse 8, 53115 Bonn, Germany
| | - L Ratschbacher
- Institut für Angewandte Physik der Universität Bonn, Wegelerstrasse 8, 53115 Bonn, Germany
| | - Y Völzke
- Institut für Angewandte Physik der Universität Bonn, Wegelerstrasse 8, 53115 Bonn, Germany
| | - D Meschede
- Institut für Angewandte Physik der Universität Bonn, Wegelerstrasse 8, 53115 Bonn, Germany
| |
Collapse
|
46
|
Barrio J, Errando CL, García-Ramón J, Sellés R, San Miguel G, Gallego J. Influence of depth of neuromuscular blockade on surgical conditions during low-pressure pneumoperitoneum laparoscopic cholecystectomy: A randomized blinded study. J Clin Anesth 2017; 42:26-30. [DOI: 10.1016/j.jclinane.2017.08.005] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2017] [Revised: 07/24/2017] [Accepted: 08/03/2017] [Indexed: 01/07/2023]
|
47
|
Rioux JA, Gallego J, Jarry DM, Guilvard E, Maazoun R, Périères J, Becqueriaux L, Belmonte A. Un phlébotome nouveau pour l’Espagne. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/parasite/1984594421] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
48
|
Gravalos C, Capdevila J, Layos L, Pericay C, Martínez-Villacampa M, López López C, Losa F, Safont M, Gómez-España A, Alonso V, Escudero P, Gallego J, García-Paredes B, Palacios A, Biondo S, Salazar R, Aranda Aguilar E. Phase II randomized trial of capecitabine + radiation therapy with/without bevacizumab as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: Final results of 3 and 5-year disease free survival, distant relapse free survival and overall survival. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Fernández A, Salgado M, García A, Buxò E, Vera R, Adeva J, Jiménez P, Quintero G, Llorca C, Cañabate M, López L, Muñoz A, Ramírez P, González P, López C, Reboredo M, Gallardo E, Sánchez M, Gallego J, Guillén C. Treatment patterns, clinical characteristics, and outcomes of patients (pts) with metastatic pancreatic cancer (MPC) treated with nab-paclitaxel (nab-P) plus gemcitabine (GEM) in real-life practice: ANICE-Pac trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
50
|
Jiménez Fonseca P, Carmona-Bayonas A, Hernández R, Custodio A, Cano JM, Lacalle A, Echavarria I, Macias I, Mangas M, Visa L, Buxo E, Álvarez Manceñido F, Viudez A, Pericay C, Azkarate A, Ramchandani A, López C, Martinez de Castro E, Fernández Montes A, Longo F, Sánchez Bayona R, Limón ML, Diaz-Serrano A, Martin Carnicero A, Arias D, Cerdà P, Rivera F, Vieitez JM, Sánchez Cánovas M, Garrido M, Gallego J. Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry. Br J Cancer 2017; 117:775-782. [PMID: 28765618 PMCID: PMC5589993 DOI: 10.1038/bjc.2017.245] [Citation(s) in RCA: 57] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2017] [Revised: 06/19/2017] [Accepted: 07/04/2017] [Indexed: 12/17/2022] Open
Abstract
Background: The choice of chemotherapy in HER2-negative gastric cancer is based on centre’s preferences and adverse effects profile. No schedule is currently accepted as standard, nor are there any factors to predict response, other than HER2 status. We seek to evaluate whether Lauren type influences the efficacy of various chemotherapies and on patient overall survival (OS). Methods: We have conducted a multicenter study in 31 hospitals. The eligibility criteria include diagnosis of stomach or gastroesophageal junction adenocarcinoma, HER2 negativity, and chemotherapy containing 2–3 drugs. Cox proportional hazards regression adjusted for confounding factors, with tests of ‘treatment-by-histology’ interaction, was used to estimate treatment effect. Results: Our registry contains 1303 tumours analysable for OS end points and 730 evaluable for overall response rate (ORR). A decrease in ORR was detected in the presence of a diffuse component: odds ratio 0.719 (95% confidence interval (CI), 0.525–0.987), P=0.039. Anthracycline- or docetaxel-containing schedules increased ORR only in the intestinal type. The diffuse type displayed increased mortality with hazard ratio (HR) of 1.201 (95% CI, 1.054–1.368), P=0.0056. Patients receiving chemotherapy with docetaxel exhibited increased OS limited to the intestinal type: HR 0.65 (95% CI, 0.49–0.87), P=0.024, with no increment in OS for the subset having a diffuse component. With respect to progression-free survival (PFS), a significant interaction was seen in the effect of docetaxel-containing schedules, with better PFS limited to the intestinal type subgroup, in the comparison against any other schedule: HR 0.65 (95% CI, 0.50–0.85), P=0.015, and against anthracycline-based regimens: HR 0.64 (95% CI, 0.46–0.88), P=0.046. Conclusions: As a conclusion, in this registry, Lauren classification tumour subtypes predicted survival and responded differently to chemotherapy. Future clinical trials should stratify effect estimations based on histology.
Collapse
Affiliation(s)
- Paula Jiménez Fonseca
- Department of Medical Oncology, Central de Asturias University Hospital, Oviedo 33011, Spain
| | - Alberto Carmona-Bayonas
- Department of Hematology and Medical Oncology, Morales Meseguer University Hospital, Murcia 30008, Spain
| | - Raquel Hernández
- Department of Medical Oncology, Canarias University Hospital, Tenerife 38320, Spain
| | - Ana Custodio
- Department of Medical Oncology, La Paz University Hospital, Madrid 28046, Spain
| | - Juana Maria Cano
- Department of Medical Oncology, Ciudad Real General Hospital, Ciudad Real 13005, Spain
| | - Alejandra Lacalle
- Department of Medical Oncology, Complejo Hospitalario de Navarra, Pamplona 31008, Spain
| | - Isabel Echavarria
- Department of Medical Oncology, Gregorio Marañón University Hospital, Madrid 28007, Spain
| | - Ismael Macias
- Department of Medical Oncology, Parc Tauli University Hospital, Sabadell 08208, Spain
| | - Monserrat Mangas
- Department of Medical Oncology, Hospital Galdakao-Usansolo, Galdakao-Usansolo 48960, Spain
| | - Laura Visa
- Department of Medical Oncology, El Mar University Hospital, Barcelona 08003, Spain
| | - Elvira Buxo
- Department of Medical Oncology, Hospital Clinic, Barcelona 08036, Spain
| | | | - Antonio Viudez
- Department of Medical Oncology, Complejo Hospitalario de Navarra, Pamplona 31008, Spain
| | - Carles Pericay
- Department of Medical Oncology, Parc Tauli University Hospital, Sabadell 08208, Spain
| | - Aitor Azkarate
- Department of Medical Oncology, Son Espases University Hospital, Mallorca 07120, Spain
| | - Avinash Ramchandani
- Department of Medical Oncology, Insular de Gran Canaria University Hospital, Las Palmas de Gran Canaria 35016, Spain
| | - Carlos López
- Department of Medical Oncology, Marqués de Valdecilla University Hospital, Santander 39008, Spain
| | - Eva Martinez de Castro
- Department of Medical Oncology, Marqués de Valdecilla University Hospital, Santander 39008, Spain
| | - Ana Fernández Montes
- Department of Medical Oncology, Complejo Hospitalario de Orense, Orense 32005, Spain
| | - Federico Longo
- Department of Medical Oncology, Ramón y Cajal University Hospital, Madrid 28034, Spain
| | | | - Maria Luisa Limón
- Department of Medical Oncology, Virgen del Rocío University Hospital, Sevilla 41013, Spain
| | - Asun Diaz-Serrano
- Department of Medical Oncology, 12 de Octubre University Hospital, Madrid 28041, Spain
| | | | - David Arias
- Department of Medical Oncology, Complejo Hospitalario de Orense, Orense 32005, Spain
| | - Paula Cerdà
- Department of Medical Oncology, Tecknon Cancer Institute, Barcelona 08022, Spain
| | - Fernando Rivera
- Department of Medical Oncology, Marqués de Valdecilla University Hospital, Santander 39008, Spain
| | - Jose Maria Vieitez
- Department of Medical Oncology, Central de Asturias University Hospital, Oviedo 33011, Spain
| | - Manuel Sánchez Cánovas
- Department of Hematology and Medical Oncology, Morales Meseguer University Hospital, Murcia 30008, Spain
| | - M Garrido
- Department of Medical Oncology, Pontificia Universidad Católica de Chile, Santiago de Chile, Chile
| | - J Gallego
- Department of Medical Oncology, Elche University Hospital, Elche 03203, Spain
| |
Collapse
|